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6A. Zusammenfassung
Die DNS-Methylierung ist eine epigenetische Modifikation, die in der
Ausprägung des Phänotyps mitwirkt ohne die DNA Sequenz zu verändern und somit
eine bedeutende Rolle in der Entwicklung als auch bei Krankheiten spielt. Die
genomische Prägung wird definiert als parental-spezifische monoallelische
Expression. Eine wesentliche Eigenschaft der genomischen Prägung ist, dass
geprägte Gene geclustert vorliegen und innerhalb dieses Clusters ein Gen für eine
makro-nicht-kodierende RNS kodiert. Es wurde bereits gezeigt, dass makro-nicht-
kodierende RNS durch DNS-Methylierung kontrolliert werden können.  In der Maus
wird beispielsweise die nicht kodierende RNS Airn ausschließlich vom paternalen
Allel exprimiert, da dieses keine DNS-Methylierung („der Imprint“) am Promotor
aufweist. Das maternale Allel hingegen weist eine DNS-Methylierung am Promotor
auf und sorgt somit für die Unterdrückung der Expression von Airn. Airn sorgt für die
Stilllegung von Igf2r in cis und führt weiters dazu, dass der Promotor von Igf2r
methyliert wird. Dadurch wird Igf2r nur vom mütterlichen Allel exprimiert. Aufgrund
dessen stellt sich die Frage, ob die DNS-Methylierung die Expression von makro-
nicht-kodierenden RNS(s) in allen geprägten Clustern von Säugern kontrolliert. Ich
setzte ein in vitro System für die Demethylierung von humanen Vorhaut-
Fibroblasten (Hs-27) auf. Für diesen Zweck verwendete ich einen S-Phasen
abhängigen DNS Methyltransferaseinhibitor namens 5-aza-2’-deoxycytidin
(Decitabine), der die „Erhaltungs“-DNS Methyltransferase DNMT1 abfängt und somit
deren enzymatische Reaktion verhindert. Dies führt dann zu einem passiven Verlust
der DNS Methylierung. Um den DNS-Methylierungszustand zu überprüfen,
verwendete ich DNS Blot Analyse in Kombination mit methyl-sensitiven
Restriktionsenzymen. Die Genexpression überprüfe ich mittels qPCR und RNS
Expressions-Tiling-Arrays. Das Resultat zeigt, dass die Behandlung von Hs-27
Zellen mit Decitabine zu einem geringen Verlust der DNS-Methylierung in den
untersuchten Regionen führt. Die Expression der nicht-kodierende RNS H19 und
des MAGE-A1 Gens wurde durch die Decitabine Behandlung induziert. Es kann
jedoch nicht ausgeschlossen werden, dass die induzierte Expression aufgrund eines
sekundären Effektes von Decitabine zustande kam anstatt ein direkter Effekt der
DNS-Demethylierung zu sein, da diese nicht komplett war.
7B. Abstract
DNA methylation is an epigenetic modification that contributes to the pheno-
type without changing the DNA sequence, and has a high impact on development
and disease. Genomic imprinting is defined as parental-specific monoallelic gene
expression. A key feature of genomic imprinting is that most imprinted genes are
clustered and contain at least one macro non-coding RNA (ncRNA). It has been
shown that macro ncRNAs can be controlled by DNA methylation. For instance, the
mouse Airn ncRNA is exclusively expressed from the paternal allele due to the ab-
sence of a methylation mark (“the imprint”) on its promoter. The maternal allele in-
stead contains a methylated Airn promoter, which prevents Airn expression from this
allele. Airn silences the Igf2r protein-coding gene in cis and triggers methylation of
the Igf2r promoter. Igf2r is therefore only expressed from the maternal allele. There-
fore it is tempting to hypothesize whether DNA methylation controls macro ncRNA
expression in all mammalian imprinted gene clusters. I set up an in vitro system to
demethylate human foreskin fibroblasts (Hs-27 cells). For this purpose I used the S-
phase dependent DNA methyltransferase inhibitor 5’aza-2’-deoxycytidine (Decit-
abine) that leads to the trapping of the maintenance DNA methyltransferase DNMT1
during replication, thus inhibiting its enzymatic properties and resulting in a passive
loss of DNA methylation. To check the cells DNA methylation status, I used Southern
blot analysis with methylation-sensitive restriction enzymes. Gene expression was
assayed by qPCR and by RNA expression tiling array. These results reveal that the
treatment with Decitabine leads to a slight partial loss of DNA methylation on the re-
gions subjected to investigation. The H19 ncRNA and the MAGE-A1 gene showed
an induction of gene expression upon DAC treatment. However, as the loss of DNA
methylation was not complete, it can not be excluded, that the observed expression
of DNA methylation associated genes was due to secondary effects of the DAC
treatment rather than a reduction of DNA methylation.
81. Introduction
1.1 DNA methylation
1.1.1 Overview
DNA methylation is an epigenetic modification whose correct setting is essen-
tial for normal development. In mammals, the target is a 5’ cytosine located next to a
guanine, separated by a phosphate group, and is called CpG dinucleotide. This
mark, once established during development, is stable propagated through subse-
quent cell divisions. DNA methylation plays pivotal roles in genomic imprinting, X-
inactivation, formation of centromers and silencing of retroviral elements (retrotrans-
posons). Besides its contribution to develop a healthy organism, DNA methylation is
a fundamental player in a variety of disease for instance Rett-, ICF-syndrome (im-
munodeficiency, centromere instability, facial abnormalities) and cancer. Although a
number of studies have shown that DNA methylation correlates with transcriptional
repression, up to now evidence proving that DNA methylation is responsible for gene
silencing is lacking. However, genomic imprinting states the exception and illustrates
that DNA methylation can be the key player for transcriptional repression of macro
ncRNAs.
1.1.2 DNA methyltransferases
The first DNA methyltransferase to be identified was Dnmt1, the maintenance
methyltransferase (Bestor and Ingram 1983; Bestor 1988). The hypothesis of a
maintenance mechanism dates back to the 1970s. Holliday, Plugh and Riggs pro-
posed a model by which an, at that time unidentified, enzyme is involved in a repli-
cation dependent manner to inherit the marks onwards to the unmethylated, newly
synthesized strand (Holliday and Pugh 1975; Riggs 1975). The CpG dinucleotide is a
palinodromic sequence. Through semiconservative replication one parental strand
remains methylated at the CpG site whereas the newly synthesized strand contains
unmethylated CpG sites. In agreement with this model, it was shown that the main
targets for Dnmt1 are CpG sites (Bestor and Ingram 1983). In more detail it was re-
ported, that Dnmt1 has a 5-30 fold higher preference for hemimethylated DNA, al-
9though this does not exclude any de novo activity (Yoder, Soman et al. 1997; Bestor
2000). Knock out of Dnmt1 is embryonic lethal at E9.5 showing abnormal imprinted
gene expression and reactivation of retrotransposons (see Table 1) (Li, Bestor et al.
1992; Li, Beard et al. 1993; Lei, Oh et al. 1996). A question considered with high cu-
riosity was to elucidate if Dnmt1 is the sole protein that is involved in DNA methyla-
tion. The key experiment was conducted by Lei et al and brought the final evidence:
Upon deleting Dnmt1, de novo methylation marks were not impaired (Lei, Oh et al.
1996). This demonstrated that additional enzymes are involved in the DNA methyla-
tion process. Importantly, annotations of expressed sequence tags served as a pro-
found tool for the characterization and identification of the de novo enzymes. The
first candidate, Dnmt2 showed no DNA methyltransferase activity, instead it is re-
sponsible for methylation of the tRNAAsp anticodon loop at cytosine 38 (Yoder and
Bestor 1998; Goll, Kirpekar et al. 2006; Rai, Chidester et al. 2007). Therefore knock
out of this protein had no effect on the DNA methylation status. Identification,
through EST search, of Dnmt3a and Dnmt3b followed (Okano, Xie et al. 1998).
Dnmt3a is responsible for setting imprints during spermatogenesis or oogenesis. The
lack of this enzyme or an additional factor Dnmt3L which lacks methyltransferase
activity but enhances the activity of Dnmt3a and Dnmt3b leads to failure in the es-
tablishment of imprints (Hata, Okano et al. 2002; Kaneda, Sado et al. 2004). The
disruption of Dnmt3a is lethal and embryos die 4-8 weeks after birth (see Table 1). In
addition, the major function mediated by Dnmt3b is the silencing of repetitive ele-
ments. Knock out experiments have shown that Dnmt3b-/- embryos display demeth-
ylated satellite repeats and die at E14.5. Moreover, in humans a point mutation in the
catalytic motif of DNMT3B leads to the hypomethylation of satellite repeats that are
primarily located at the pericentromeric region of chromosome 1, 9 and 16. This ob-
servation is called the ICF syndrome:  immunodeficiency, centromere instability and
facial abnormality (Ehrlich 2003). Further, the structural motifs outline their relation-
ship to each other and highlight that DNA methylation is a conserved mechanism,
not restricted to eukaryotes. In prokaryotes DNA methylation exerts its function as a
host immune system by defending the organism from invading parasitic elements.
Besides preventing the transposition of transposons in eukaryotes, in this way also
acting as a defense system, DNA methylation has also an important impact on de-
velopment.
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Table 1: Functional aspects of the DNA methyltransferases
This illustrates that the process of DNA methylation is not restricted to a certain
kingdom and conservation is reflected in the structure of all DNA methyltransferases,
mainly the catalytic domain. In all eukaryotic DNA methyltransferases (Dnmt1,
Dnmt2, Dnmt3a, Dnmt3b) this domain is highly related to bacterial methyltrans-
ferases (Bestor 1988). DNA methyltransferases contain up to 10 motifs whereby 6 of
them are highly conserved and involved in the enzymatic reaction. In contrast, the N-
terminal domain fulfils regulatory functions and thus differs in function and length
between the different Dnmts. Dnmt1, a 1620 amino acid long protein, contains an N-
terminal domain that is separated from the catalytic domain by a Glycin-Lysine re-
peat region. It exhibits certain specific functional motifs. For instance it contains a
nuclear localization signal and can interact with PCNA. The RFT motif is responsible
for replication foci targeting and thus provides the ability to discriminate for
hemimethylated DNA. Additionally, a cysteine-rich domain for interaction with DNA
sequences and a BAH motif for protein-protein interactions are also present. Dnmt2
is 415 amino acids in length and completely lacks the N-terminal domain. Therefore
no maintenance function would be predicted. It was shown that this enzyme also
completely lacks de novo DNA methyltransferase activity (Okano, Xie et al. 1998).
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Figure 1: The structure of the eukaryotic DNA methyltransferases: black box includes the catalytic
domains of Dnmt1, Dnmt3a, Dnmt3b, Dnmt2 and Dnmt3L that are conserved and mediate the enzy-
matic reaction with the exception of Dnmt3L and Dnmt2. Orange box includes the regulatory N-
terminal domain, that is different in length between the different Dnmts. (PCNA) domain for the inter-
action with PCNA during replication, (NLS) nuclear localization signal, (RFT) replication foci targeting,
(CXXC) cysteine-rich domain for DNA sequence binding, (BAH) protein-protein interaction domain,
(PWWP) heterochromatin association domain, (ATRX) C2-C2 zinc-finger domain involved in protein-
protein interactions  (Cheng and Blumenthal 2008)
The N-terminal structure of Dnmt3a, a protein of 908 amino acids in length,
contains a PWWP domain and a cysteine rich domain (ATRX). The former one is
responsible for DNA binding and the latter one mediates protein-protein interactions.
The same motifs are present in the structure of Dnmt3b, an 859 amino acid long en-
zyme. It has been shown that the activity of de novo enzymes is enhanced by the
Dnmt3L protein (Hata, Okano et al. 2002). With 387 amino acids it is much shorter in
length and shows no methyltransferase activity (Figure 1).
1.1.3 The enzymatic mechanism of DNA methylation
The covalent “Michael addition” is the main reaction mechanism of how the
DNA methyltransferase modify CpG sites in the double helix, which then reside in
the major groove of the B-DNA.  As mentioned above, the catalytic domain is con-
served between eukaryotes and prokaryotes and is involved in the enzymatic reac-
tion.  All DNA methyltransferases (Dnmts) share an IV and VI motif in their catalytic
12
domain. The Dnmt targets the cytosine on carbon 6 via motif IV, which provides a
reactive thiol group. As a consequence a covalent bond at position 6 between the
Dnmt and cytosine is formed, thereby converting the carbon 5 into a highly reactive
carbanion. The carbanion at position 5 is then able to a nucleophil attack of the
methyl donor, which is for all Dnmts S-adenosyl-L-methionin. This leads to the addi-
tion of a methyl group to position 5 of the cytosine. The base is additionally targeted
by the motif VI, which stabilizes the enzyme-cytosine intermediate via hydrogen
bonds to the amino group on position 4. Subsequently, the enzyme is released
through proton abstraction at position 5 and the double bond between carbon 5 and
6 is reverted. This step is also known as β-elimination (Figure 2). A major mainly un-
solved issue that needs further investigation is to find out how Dnmts are targeted to
their sites. It has been shown that Dnmt1 interacts during replication with PCNA
(Leonhardt, Page et al. 1992). More recently, it has been reported that the UHRF1
protein is able to interact via the SRA domain with hemimethylated DNA. Thereby
the methylated cytosine undergoes base flipping by rotating around the phosphate
backbone breaking up the hydrogen bonds with guanin and reaching out of the dou-
ble helix. In this way UHRF1 is able to interact stably with the DNA and recruits
Dnmt1 to their target sites (Arita, Ariyoshi et al. 2008; Hashimoto, Horton et al.
2008). How de novo Dnmts target sites subjected to DNA methylation still remains
elusive.
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Figure 2: Covalent “Michael addition” reaction of the DNA methyltransferase: (I) The Dnmt targets
carbon 6 via the motif IV that provides a thiol group and via motif VI nitrogen at position VI. (II) A co-
valent bond is formed between the Dnmt and cytosine and this intermediate is in addition stabilized
via hydrogen bonds between a proton of the amino group at position 4 and oxygen of motif VI. The
active carbanion at position 5 attacks the methyl group from the donor S-adenosyl-L-methionin (III).
Proton abstraction at position 5 (β-elimination) leads to the release of the Dnmt from 5-Methylcytosine
(IV).
1.1.4 CpG islands vs. CpG sites
 70% of all CpG sites throughout the human genome are methylated (Ehrlich,
Gama-Sosa et al. 1982). Most of these methylated CpG sites are located in repeti-
tive elements residing in intergenic and/or intronic regions (Miranda and Jones
2007).  Interestingly, the CpG dinucleotide is underrepresented in the human ge-
nome due to the ease of subjecting methylated CpG sites to a deamination reaction.
Methylated CpG sites are a mutational hotspot and are converted to a thymine thus
leading to a permanent inactivation of retrotransposons. Nevertheless, a small pro-
portion of CpG dinucleotides has accumulated to a high density in certain promoter
regions. In this context the CpG sites are called CpG islands. A general definition
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states these stretches as CpG sites longer than 500bp with CpG content greater
than 55% (Takai and Jones 2002). CpG islands are located at the 5’ region of a gene
and can spread through the first exon (Bird 1986). Promoters of approximately 50%
of the human genes contain CpG islands including housekeeping genes and a re-
stricted number of tissue specific genes. The hallmark of a CpG island is that they
are free of DNA methylation in a healthy cell, with exceptions like the inactive X-
chromosome in females and CpG island promoters of imprinted genes.
A common hallmark of cancer is aberrant DNA methylation. A cancer cell of-
ten reflects this by hypomethylated repetitive elements and hypermethylated CpG
islands on tumor suppressor genes or housekeeping genes. In this context DNA
methylation contributes strongly to chromosomal instability (Esteller 2008).
1.1.5 DNA methylation and gene expression
DNA methylation can affect the transcription of genes. This is primarily by the
fact that methylated CpG sites are located in the major groove, the place were tran-
scription factors bind to their target sequence and initiate the transcription of a gene.
However when the CpG sites are methylated the binding of transcription factors can
be prevented as it was shown for the insulator CTCF in case of the Igf2 cluster (Bell,
West et al. 2001).
In addition, of all epigenetic modifications DNA methylation is the only one
that can modify the nucleotide sequence directly. In this context it should be noted
that the DNA sequence in eukaryotes is packaged into chromatin. Chromatin con-
tains the nucleotide sequence and associated proteins. The sole unit of the chroma-
tin is the nucleosome that consists of basic histone proteins. One single nucleosome
is made up of 8 histone proteins namely two of each H2A, H2B, H3 and H4. Roughly
146bp of DNA are wrapped around one nucleosome. Of great importance is that
chromatin is either present in a densely packed conformation, that is referred to as
heterochromatin or in a less densely packed conformation, named euchromatin.
Both of these stages, heterochomatin and euchromatin correlate with chemically
modified residues in the amino-terminal tails of histone proteins that protrude out of
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the nucleosome. The most prominent ones are histone-methylation, -acetylation and
-phosphorylation. Euchromatin-associated active marks are acetylation of histone 3
and 4 (H3ac/H4ac), methylation of lysine 4 of histone 3 (H3K4me). Heterochromatin-
associated repressive marks are histone methylation of lysine 9 of histone 3
(H3K9me), H3 trimethylation of lysine 27 (H3K27me3), H4 methylation of lysine 20
(H4K20me) (Jenuwein and Allis 2001). Importantly, DNA methylation and histone
modifications are linked to each other. Methylated DNA can serve as a target for
certain proteins. For instance it was shown in a study of Jones et al that the methyl-
CpG binding protein MeCP2, a repressor of transcription, binds to methylated CpG
sites. MeCP2 interacts with the Sin3a complex that has histone deacetylase activity.
Thereby acetylation marks are removed and an altered closed chromatin structure is
established. Consequently, initiation of the transcription is prevented (Jones, Veen-
stra et al. 1998).
1.1.6 DNA methylation has 4 main roles
DNA methylation has an essential role in genomic imprinting (definition see in
1.2) and X-inactivation. An initial study of Li et al pointed out that mice which lack the
Dnmt1 on both alleles show biallelic repression of the Igf2 (normally expressed only
from the paternal allele) and Igf2r gene (normally expressed only from the maternal
allele) as well as biallelic expression of the H19 ncRNA (normally expressed only
from the maternal allele). Therefore, this shows that DNA methylation is essential for
genomic imprinting (Li, Beard et al. 1993). X-inactivation is a developmental dosage
compensation process in females by which one of the two X chromosomes gets in-
activated. The role of DNA methylation in X-inactivation is to regulate expression of
the macro ncRNA Xist. On the inactive chromosome the Xist promotor is unmethy-
lated leading to Xist expression. On the active X chromosome the Xist promotor is
hypermethylated, thus preventing the expression of Xist on the active X chromosome
(Norris D.P. 1994). DNA methylation also plays an important role in the formation of
centromers. Segregation of the chromosomes during mitosis is achieved through the
attachment of microtubules to the centromere, a highly heterochromatic region. The
centromere consists of repetitive DNA elements that are tandemly arranged and the
basic unit is the satellite repeat. The correct formation of the centromere and accu-
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rate chromosome segregation relies on DNA methylation. For instance, it has been
shown that a point mutation in the DNMT3B enzyme correlates with hypomethylated
satellite repeats that are located within the pericentromeric regions of chromosome
1, 9 and 16 causing the ICF syndrome (immunodeficiency, centromere instability and
facial abnormality) (Ehrlich 2003).  Another feature that highlights the importance of
DNA methylation is the silencing of retroviral relicts that inserted in the human ge-
nome through evolution. Transposons can be subdivided into two classes: retro-
transposons (class I) which move via an RNA intermediate into new sites or DNA
transposons (class II) which copy themselves via a “cut and paste” mechanism with
the help of the transposase into a new genomic location. These elements are subject
to DNA methylation to prevent their transposition. Therefore DNA methylation con-
tributes strongly to chromosomal stability and prevents translocation and DNA rear-
rangements (Bourc'his and Bestor 2004; Goll and Bestor 2005).
1.2 Genomic imprinting as a model for studying epigenetic mechanisms
1.2.1 Genomic imprinting – overview
Uniparental disomy (UPD) is a phenomenon in which an organism contains a
duplication of a chromosome or parts of it from one parent and lacks this or these
parts from the other parent. In addition to uniparental duplications also uniparental
deletions can happen. Individuals that carry a deletion on a chromosome, which was
inherited from one parent and the respective wild type chromosome inherited from
the other parent have uniparental deletions. This laid the foundation for studying the
phenomenon of genomic imprinting. Key experiments were conducted in the 1980s.
Through nuclear transfer experiments diploid uniparental embryos in different com-
binations of the genomes were set up. Androgenetic embryos contain two paternal
genomes whereas gynogenetic embryos harbor twice the maternal genome, in con-
trast to wild type embryo that contains a paternal and maternal genome. The results
showed that the only viable combination is the embryo that received a paternal and
maternal chromosome set (McGrath and Solter 1984; McGrath and Solter 1984;
Surani, Barton et al. 1984). These results pointed out that gynogenetic embryos
have defects in the tissues that contribute to development of placenta and androge-
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netic embryos had defects in embryonic tissues, resulting in the death of the embryo
(Barlow and Bartolomei 2007). Experiments with some UPDs in mice have shown
that opposite outcomes are the results when single chromosomes or pieces are pre-
sent either twice from the mother or from the father (Cattanach and Kirk 1985).
These outcomes were manifested in the size of the offsprings. These experiments
pointed out that for a proper development of an organism both genomes, the mater-
nal and the paternal, are essential. However, inbred mice with the identical sequence
on both alleles are also subjected to genomic imprinting, thus indicating that the
mechanism is not restricted to the DNA sequence itself. However, more likely an
epigenetic mechanism must operate to treat the alleles differentially. In this way the
only time point to distinguish between the identical maternal and paternal allele is
when they are separated during gametogenesis.
The discovery of the first imprinted genes is dated back in the early 1990s,
when the imprinted Igf2r gene on mouse chromosome 17 was observed (Barlow,
Stoger et al. 1991). The discovery of the imprinted Igf2 on mouse chromosome 7
followed (DeChiara, Robertson et al. 1991) with the imprinted non-coding RNA H19
(Bartolomei, Zemel et al. 1991).
1.2.2 Characteristics of genomic imprinting
Genomic imprinting is defined as parental-specific monoallelic gene expres-
sion. Diploid organisms contain a set of chromosomes inherited from the mother and
from the father. Thus, each gene is present twice in the organism and the majority of
genes show biallelic expression. For a small subset of genes this is not the case.
Their expression is either restricted to the maternal or the paternal copy, and these
genes are so-called imprinted genes.
Up to now approximately 90 imprinted genes have been identified and most
b u t  n o t  a l l  o f  t h e m  r e s i d e  i n  c l u s t e r s
(http://www.mgu.har.mrc.ac.uk/research/genomic_imprinting) (Verona, Mann et al.
2003). The length of an imprinted cluster is variable, can be up to 4000kb and can
harbor up to 12 protein coding genes but at least one gene encodes for a macro
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ncRNA (Koerner, Pauler et al. 2009). A hallmark of imprinted genes is that most of
them are associated with CpG islands (Paulsen, El-Maarri et al. 2000). Within or
juxtaposed these CpG islands direct repeats are often present and it is hypothesized
that they might be the attractors for the de novo methylation during gametogenesis,
since repeats are subject to DNA methylation as a response of a defense mecha-
nism (Neumann, Kubicka et al. 1995).
The imprint is a DNA methylation mark set on a differentially methylated re-
gion (DMR) either during spermatogenesis or oogenesis on the paternal or maternal
chromosome, respectively. Such a DMR is called a gametic DMR, (Ferguson-Smith,
Sasaki et al. 1993; Stoger, Kubicka et al. 1993). Furthermore, also somatic DMRs
are found within imprinted genes, but those acquire the imprint later during develop-
ment, when the embryo is diploid (Stoger, Kubicka et al. 1993; Olek and Walter
1997). The unmethylated gametic DMR is the regulatory element that controls the
cluster in cis. This differs from trans-acting mechanisms in the way that the regula-
tory function is restricted to the same chromosome and can not act on other chromo-
somes (Barlow and Bartolomei 2007). If deletion of an unmethylated DMR results in
loss of imprinted expression of all genes in a cluster, this DMR can be defined as an
imprint control element (ICE) because it acts on the whole imprinted cluster and is
pivotal for proper parental specific expression (Spahn and Barlow 2003).
Chromatin modifications have also been shown to be involved in modifying
the ICE. The methylated ICE carries focal repressive histone marks for instance
H3K9me3, the associated HP1 protein and H4K20me2 (Mikkelsen, Ku et al. 2007;
Regha, Sloane et al. 2007). On the contrary, the unmethylated ICE is marked with
active histone marks like H3/H4 acetylation and H3K4me. As described above chro-
matin is either present as euchromatin or heterochromatin and is associated with
active or repressive histone marks. However, the observation of focal heterochro-
matin marks demonstrated that for instance repressive histone marks can be present
in the body of a gene without constraining the elongation of polymerase II that runs
through an actively transcribed gene.
Imprinted genes have a high functional impact in the development of an em-
bryo ranging from the growth of the embryo or placenta to behavioral aspects after
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birth including diseases like autisms and schizophrenia (Reik and Walter 2001). Up
to now, six imprinted cluster in mouse have been intensively characterized with two
paternally imprinted clusters - Igf2 and Dlk1 - and four maternally imprinted clusters
PWS, Gnas, Kcnq1 and Igf2r. The Igf2r cluster will be described in detail later.
1.2.3 The imprint life cycle and reprogramming
DNA methylation marks on DMRs are erased in primordial germ cells, estab-
lished in mature germ cells and maintained after fertilization throughout the life of an
organism. Primordial germ cells undergo a genome wide demethylation event at
around embryonic day 12-13 (Brandeis, Kafri et al. 1993; Tada, Tada et al. 1998),
and the DMRs of imprinted genes are subjected to de novo methylation at late fetal
stage (Figure 3A) (Kafri, Ariel et al. 1992; Brandeis, Kafri et al. 1993). A second
wave of genome wide DNA demethylation occurs immediately after fertilization.
Thereby the paternal genome undergoes an active demethylation event (Oswald,
Engemann et al. 2000) and later the maternal genome looses its methylation marks
passively (Howlett and Reik 1991). Interestingly, imprinted genes escape somehow
this second demethylation event and therefore they maintain their imprints (reviewed
(Reik and Walter 2001; Li 2002). How imprinted genes are protected remains an un-
answered question up to now (Monk, Boubelik et al. 1987). At the blastocyst stage
around E3.5 most of the genome is demethylated but the DNA methylation marks
will be established newly during implantation by the action of de novo enzymes.
Throughout implantation the ectoderm and mesoderm become hypermethylated
contrasting the primitive endoderm and trophoblast (Figure 3B).
Figure 3A: The imprint life cycle:
As an example, the imprint con-
trol element 1 (ICE1) and ICE2
are shown: the black box carries
a methylation mark and the white
box is unmethylated leading to
imprinted expression in the em-
bryo. During gametogenesis the
imprints are erased in early pri-
mordial germ cells (PGCs) and
restablished in mature gametes.
When the embryo becomes dip-
loid the imprints are maintained
(Reik and Walter 2001).
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Figure 3B: Reprogramming during embryonic development: Immediately after fertilization a second
demethylation event takes place. First, the paternal genome undergoes an active demethylation proc-
ess (I) followed by a passive event (II) of the maternal genome. At embryonic day 3.5 (E3.5) the
blastocyst displays a genome wide demethylation pattern followed by de novo methylation after im-
plantation in the embryonic ectoderm and mesoderm, contrasting the primitive endoderm and tro-
phoblast. In terms of X-inactivation in the extraembryonic part an imprinted mode is favored whereas
in the embryonic part X-inactivation occurs randomly random (Li 2002)
1.2.4 The Insulin-like growth factor type 2 receptor (Igf2r)-cluster
In general, the Igf2r cluster harbors genes that underlie either biallelical or
monoallelical expression that can be further manifested in a tissue- specific manner
and expression of some genes is specific to a certain developmental stage. The
genes Mas1 and Slc22a1 (solute carrier family 22 member 1) are expressed from
both alleles. Igf2r (Barlow, Stoger et al. 1991), Slc22a2 and Slc22a3 are expressed
exclusively from the maternal allele, contrasting Airn (Lyle, Watanabe et al. 2000)
that is expressed only from the paternal allele. Imprinted expression of Igf2r and Airn
is nearly present in all tissues of mice with a few exceptions like preimplantation em-
bryos, undifferentiated ES cells, testes and neurons (Wang, Fung et al. 1994; Szabo
and Mann 1995; Szabo and Mann 1995; Lerchner and Barlow 1997; Yamasaki, Ka-
yashima et al. 2005). Slc22a2 and Slc22a3 show imprinted expression only in ex-
traembryonic tissues. Imprinted expression of Slc22a3 is restricted to a certain de-
velopmental stage. It shows imprinted expression at 11.5 dpc (days per coitum) and
switches to biallelic expression at 15.5 dpc. On the other hand, Slc22a2 is imprinted
in both of these stages (Verhaagh, Schweifer et al. 1999; Zwart, Sleutels et al.
2001).
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In more detail, the mouse Igf2r cluster spans 490kb on chromosome 17 and
contains three protein-coding genes (Igf2r, Slc22a2 and Slc22a3) that are
exclusively expressed from the maternal chromosome. While silencing of these 3
protein-coding genes takes place on the paternal allele, the macro ncRNA Airn is
expressed from a promotor residing in intron 2 of Igf2r, known as region 2, in an-
tisense orientation with respect to Igf2r from the paternal allele. However, the ncRNA
Airn is responsible for the repression of Igf2r, Slc22a2 and Slc22a3 on the paternal
allele (Figure 4). This was shown by truncating Airn from 108kb to 3kb resulting in
loss of silencing of the imprinted genes (Sleutels, Zwart et al. 2002). Moreover, it
was also shown that if DNA methylation is missing, Igf2r is biallelically repressed (Li,
Beard et al. 1993). Importantly this cluster contains a germline DMR (gDMR) and a
somatic DMR (sDMR). The former one comprises the promoter of the macro ncRNA
Airn. Igf2r and the macro ncRNA Airn have an overlap of ~29kb with each other
(Lyle, Watanabe et al. 2000). The germline DMR (DMR2), the imprint control ele-
ment of this cluster, has a length of 3.7kb and harbors a 2kb CpG island (Stoger,
Kubicka et al. 1993; Wutz, Smrzka et al. 1997). The somatic DMR (DMR1) is located
at the Igf2r promoter and gains DNA methylation, only on the paternal allele during
development (Sleutels, Zwart et al. 2002). Furthermore, the 3’ end of the Airn tran-
script overlaps with the non-imprinted Mas1 gene (Lyle, Watanabe et al. 2000). The
macro ncRNA Airn is mostly unspliced, nuclear localized, only a minority of 5% is
spliced and cytoplasmatic located (Seidl, Stricker et al. 2006). Whereas in mice the
imprinted Ifg2r cluster shows strict imprinted expression, it only shows polymorphic
imprinted expression in humans (Xu, Goodyer et al. 1993; Smrzka, Fae et al. 1995;
Oudejans, Westerman et al. 2001; Monk, Arnaud et al. 2006).
Figure 4: The Igf2r cluster: the imprint control element (ICE) in intron 2 of the Igf2r gene is unmethy-
lated on the paternal allele leading to expression of the macro ncRNA Airn (108kb). Airn initiates the
silencing of the three protein-coding genes (Igf2r, Slc22a2 and Slc22a3) in cis. On the contrary, the
ICE on the maternal allele harbors a methylation imprint which hinders the expression of ncRNA Airn
and prevents the silencing of the 3 protein coding genes. Slc22a1 and Mas1 gene are monoallelicaly
expressed. (yellow box) imprinted genes, (white box) biallelicaly expressed genes, (s) somatic DMR,
(ICE) imprint control element or gametic DMR, (black arrow) expressed allele of an imprinted gene,
(black star) repressed allele of an imprinted gene, (green arrow) expression of the ncRNA Airn.
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1.2.5 Macro  non-coding RNAs
“DNA makes RNA makes protein” states the central dogma of modern biol-
ogy. Besides protein-coding genes, which make up 1-2% (Kapranov, Willingham et
al. 2007) of the genome, a large fraction of the genome is transcribed but not trans-
lated into a protein and this fraction is designated as non-coding RNAs (ncRNAs).
Well investigated classes of ncRNAs are involved in processes such as splicing and
translation, by excerpting introns like the small nucleolar (sno) RNAs or by convert-
ing the messenger RNA (mRNA) into a protein, namely the transfer RNA (tRNA) and
ribosomal RNA (rRNA). However, this is not all. The class of ncRNAs is much bigger
then expected. Powerful tools like genome-wide tiling arrays and cDNA sequencing
made it visible that the transcriptome encodes more non-coding transcripts then
coding transcripts (Kapranov, Cheng et al. 2007). A possible way to classify them is
by their length (small vs. macro ncRNAs) or the way they mediate their functions, in
respect to cis or trans (Koerner, Pauler et al. 2009). The class of small ncRNAs
comprises micro (mi) RNAs (22nt), short interfering (si) RNAs (21nt) and piwi inter-
acting (pi) RNAs (26-31nt). Their main function is dedicated to inhibit translation or,
in respect to piRNAs, to silence transposons, and they act in trans. On the other
hand large ncRNAs are defined as 200nt or longer (Kapranov, Cheng et al. 2007)
and are the only ncRNAs up to now that exert their functions also in cis (Koerner,
Pauler et al. 2009). Macro ncRNAs have a pivotal role in genomic imprinting. They
can occur in antisense or sense direction with respect to protein coding genes in the
cluster and can overlap a protein coding gene or lie in intergenic regions. Airn
(108kb), Kcnq1ot1 (91kb) and Nespas (30kb) are antisense macro ncRNAs, which
are transcribed from a promoter contained in the ICE. In this way the unmethylated
ICE leads to the expression of the ncRNA and its deletion results in loss of imprinting
as described above.
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1.3  Hypothesis
Although genomic imprinting is conserved in mice and humans, most of the
knowledge on how the imprinting mechanism is working is provided by using the
mouse as a model system. In the mouse a bulk of data suggests that imprinted
macro ncRNAs are directly controlled by DNA methylation (Li, Beard et al. 1993;
Shemer, Birger et al. 1997; Seidl, Stricker et al. 2006). Based on this we want to un-
tangle the question if the same is true in humans thus making a necessity to de-
methylate the nucleotide sequence. In this way I will investigate if Decitabine, a DNA
methyltransferase inhibitor, is able to demethylate the human genome, using human
foreskin fibroblasts (Hs-27 cells) as a model system and methylsensitive-restriction
enzymes combined with Southern blot as a technique. In addition I analyzed the ef-
fect of DAC on gene expression by qPCR and by RNA-chip that contains all im-
printed human regions.
1.4 DNA Demethylation
1.4.1 Ways for DNA demethylation
There are several ways to achieve a DNA demethylation effect. One would be
by targeting the DNMTs through homologous recombination. Rhee and colleagues
have shown that the DNA methylation pattern upon deletion of DNMT3B in human
cancer cell line decreases by 3%. Remarkably, the concordant deletion of DNMT1
and DNMT3B reduced the DNA methylation pattern approximately 95-fold (Rhee,
Bachman et al. 2002). A second approach that could lead to a DNA demethylation
effect is upon RNAi mediated knock down of the DNMT enzymes (Fournel, Sapieha
et al. 1999). The third approach for achieving such an effect is upon the usage of
DNA methyltransferase inhibitors. In the end, all three approaches are able to be
taken in consideration using the mouse as a model system. To demethylate the ge-
nomic sequence in humans the RNAi and the usage of DNA methyltransferase in-
hibitors would come into consideration. In my thesis I stress on the latter point, using
DNA methyltransferase inhibitors.
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1.4.2 Classes of DNA methyltransferase inhibitors
Inhibitors of the DNA methyltransferase can be subdivided into either S-phase
dependent or independent. Chemical compounds that are S-phase independent
target the active site of the DNA methyltransferase leading to a loss of DNA methy-
lation (Brueckner, Garcia Boy et al. 2005). Examples are: Procainamide, Hydra-
lazine, Psammaplin A, EGCG, MG98, RG108 (Stresemann, Brueckner et al. 2006;
Yoo and Jones 2006). On the other hand, S-phase dependent inhibitors are incorpo-
rated into the DNA and mimic a cytosine. Zebularine, 5,6-Dihydro-5-azacytidine, 5-
azacytidine and 5-aza-2’-deoxycytidine are examples of base analogues that can be
either incorporated into RNA or DNA, with the exception of the DNA restricted 5-aza-
2’deoxycytdine. These fraudulent bases are modified cytosines and differ from nor-
mal base in a way that the enzymatic reaction of the DNA methyltransferase is inhib-
ited (Figure 5A).
1.4.3 5-azacytidine (5-aza)
 5-azacytidine was one of the first compounds that were synthesized 40 years
ago as a cytotoxic chemotherapeutic agent (Sorm, Piskala et al. 1964). 5-azacytidine
is able to induce differentiation of mouse embryonic cells to muscle cells, fat cells
and chondrocytes (Taylor and Jones 1979). Roughly 20 years after the invention of
this compound Jones et al reported that 5-azacytidine also has demethylation activity
at low concentrations (Jones and Taylor 1980). Importantly, 5-azacytidine has a ri-
bose as a sugar moiety and thus to work as an inhibitor of the DNA methyltrans-
ferase it has to be converted by the ribonucleotide reductase to the deoxyribose for
incorporation into DNA. It has been shown that roughly 90% of 5-azacytidine will be
incorporated into RNA and only a small portion of 5-azacytidine gets incorporated
into DNA (Li, Olin et al. 1970). The incorporation into RNA mediates the cytotoxic
effects by affecting RNA biosynthesis.
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1.4.4 5-aza-2’deoxycytdine (Decitabine, DAC)
5-aza-2’deoxycytdine (DAC) was originally synthesized as a cytotoxic che-
motherapeutic agent at the same time as 5-aza (Sorm, Piskala et al. 1964). Con-
trasting 5-azacytidine, DAC is less toxic and has a higher efficiency for DNA methy-
lation inhibition. This is due to the fact that DAC is only incorporated into DNA and
not into RNA. To be functional, DAC has to be activated. This involves several meta-
bolic steps. First, DAC has to be taken up into the cell via membrane transporters
whereby in humans 4 classes are involved in this transport: ABC transporters, equli-
brative uniporters (SLC29A), concentrative dependent transporters (SLC28A family)
and substrate exchange transporters (SLC22/15 families) (Pastor-Anglada, Cano-
Soldado et al. 2005; Stresemann and Lyko 2008).  After cellular uptake DAC has to
be metabolized to the triphosphate level and upon competing with the cellular CTP
(cytidine triphosphate) pool, DAC is incorporated into DNA by DNA polymerase (Fig-
ure 5C). The main difference that exists between DAC and cytosine is the presence
of nitrogen instead of a carbon on position 5, which exerts the inhibitory effect on the
DNMT1. This is primarily due to the fact that DNMT1 recognizes hemimethylated
DNA. During replication, a semiconservative process, the parental strand remains
present with methylated cytosine contrasting the newly synthesized strand that ex-
hibits DAC in the DNA (this happens upon competition with the CTP pool, so it
should be taken in account that not all cytosines are replaced by DAC). DNMT1 tar-
gets hemimethylated DNA but fails to fulfil the last step of the enzymatic reaction.
The DNMT1 targets carbon 6 of cytosine, that flips out of the DNA and thus a cova-
lent bond gets formed leading to the trapping of the DNMT1. Due to the presence of
nitrogen on position 5 the last reaction step the β-elimination fails and DNMT1 is
trapped in the DNA helix (Santi, Norment et al. 1984; Christman 2002) (see Figure
5C). Accordingly, through subsequent replication cycles this leads to a passive loss
in DNA methylation. In terms of the metabolism, deoxycytidine-kinase is the main
enzyme that catalysis the phosphorylation steps for DAC in contrast to 5-azacytidine
(Stegmann, Honders et al. 1995), were Uridine-Cytidine kinase or different enzymes
might be involved. This shows that the activation of these compounds is mediated
through different enzymes.
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It is known that DAC as well as 5-azacytidine are unstable in aqueous solu-
tions. A study by Stresemann and Lyko 2008 has determined by capillary electropho-
resis experiments the difference in the half-life of 5-azacytidine and Decitabine. The
result shows that DAC exhibits a half-life of 21 hours at 37°C at a pH 7 and 5-
azacytidine of 7 hours (Stresemann and Lyko 2008).
Figure 5: Metabolism of DAC and enzymatic reaction: (A) chemical structure of cytosine, 5-
methylcytosine, Decitabine and 5-azacytidine are shown. (B) Dashed red box: Decitabine has to be
activated by conversion by the deoxycytidine kinase to the triphosphate level before the incorporation
into DNA by DNA polymerase. 5-azacytidine is activated by the Uridine–Cytidine kinase to the
triphosphate level and incorporated into RNA by the RNA polymerase. For incorporation into DNA it is
necessary that 5-azacytidne is at the diphosphate stage reduced to the deoxyribose by the action of
ribonucleotide reductase. Note that only a low amount is incorporated into DNA (Stresemann and
Lyko 2008). (C) Enzymatic mechanism of Dnmt1 in respect to DAC. The reaction is described in Fig-
ure 2 with the exception that DAC contains a nitrogen at position 5 thus leading to the trapping of
Dnmt1 due to the prevention of the β-elimination.
It should also be noted that DAC can be inhibited by cytidine deaminase. This
problem can be circumvented upon the usage of Zebularine, which is a newly de-
rived DNA methyltransferase inhibitor and also known to inhibit cytidine deaminase.
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A previous study pointed out that V5 cells (cell line transduced with a vector carrying
cytidine deaminase) showed a reduced response upon DAC treatment in contrast to
3T3 cells. However, if the cells were treated in a combinatorial manner with Zebu-
larine and DAC, they showed an enhanced response to DAC compared to 3T3 cells.
This concludes that Zebularine inhibits cytidine deaminase and increases thereby
the responds of DAC (Lemaire, Momparler et al. 2009).
1.4.5 Decitabine – differentiation, cytotoxicity and DNA demethylation
DAC, residing in the DNA, is able to induce differentiation, cytotoxicity and
DNA demethylation of cells (Jones and Taylor 1980; Creusot, Acs et al. 1982; Pinto,
Attadia et al. 1984). The cytotoxicity effect is primarily mediated upon the formation
of DNMT1-DAC adducts (Juttermann, Li et al. 1994), which have been shown to in-
duce DNA damage (Palii, Van Emburgh et al. 2008). Furthermore, a recent study
has reported that the cytotoxic effect is primarily mediated through de novo DNA
methyltransferases Dnmt3a and Dnmt3b (Oka, Meacham et al. 2005). At high con-
centrations DAC induces DNA double strand breaks thus activating repair proteins
like ATM/ATR, in addition the histone variant H2AX is recruited to the damaged site
and phosphorylated. Consequently, the cell enters into cell cycle arrest and apopto-
sis by the p53/p21 pathway (Ewald, Sampath et al. 2008). However, at low concen-
tration the main effect upon DAC treatment is DNA demethylation. This makes DAC
a potential compound to reactivate tumour suppressor genes e.g. p16 (Merlo, Her-
man et al. 1995).
An interesting issue is the remethylation of certain genes after the exposure to
DAC. A study by Bender et al has investigated the demethylation and remethylation
process upon DAC treatment in respect to the p16 promotor region.  They found that
upon DAC treatment for 24 hours the DNA methylation on the p16 promoter gets
reduced from 95% to 35%, analyzed 72 hours after the treatment. However, the
methylation marks were restablished after DAC withdrawn followed by a reduction in
the  express ion  leve l  (Bender ,  Gonza lgo  e t  a l .  1999) .
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2. Results
2.1 DNA Blot Probe design and Synthesis
2.1.1 Probe design:
To analyze loss of methylation in Hs-27 cells I designed in total 10 DNA-blot
probes from regions that were previously published as DNA methylated. The mito-
chondrial DNA is not methylated and the designed probe is used as a loading con-
trol. Table 2 lists all probe names as well as the region they detect.
Probe name Chromosomal position of
the probe
Element under
 analysis
Additional info
hH19mp chr11:1979862-1980453 H19 DMR -
hDLK1mp chr14:100343689-100344270 DLK1 DMR -
hPWSmp chr15:22620491-22621106 PWS DMR -
hOCT4mp chr6:2388804-2389335 OCT-4 TSS no CpG island
hMAGEA1mp chrX:152140930-152141536 MAGE-A1 TSS no CpG island
hHERV(gag)mp chr19:20728192-20728765 5’LTR of HERV probe is placed in gag
region
hAluJbmp chr6:160311736-160312147 SINE (AluJb) -
hL1P3mp LINE (L1P3) 5’UTR under the investiga-
tion
hSat2mp chr10:41799625-41800157 Satellite 2 repeat pericentromeric region
hMTmp chrM:6119-6662 mitochondrial probe loading control, no DNA
methylation
Bx chr6:160348427-160349007 AIRN DMR probe from Irena Vlatkovic
hKCNQ1OT1mp chr11:2676050-2676907 KCNQ1OT1 DMR from Renping Qiao
HB chr6:160309497-160310015 CpG island of IGF2R -
Table 2: Probe names are shown: h (X) mp= human(X)methylation probe; TSS= Transcription start
site.
2.1.2 PCR reactions
DNA blot probes for the regions listed in Table 2 were constructed using PCR.
For each PCR reaction MgCl2 optimization was conducted, with the best MgCl2 con-
centration the PCR was repeated shown on the right side of Figure 6A-J. Addition-
ally, a Betaine optimization (0/ 0.4/ 0.8/ 1.2M) including the best achieved MgCl2
concentration was carried out, for achieving a better result for hDLK1mp,
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hMAGEA1mp and hPWSmp. The bands on the right side (Figure 6A-I) were cut out
for cloning.
For the human H19 methylation probe (hH19mp), the best result of the PCR
was achieved with 1.2mM MgCl2 in lane 7, shown by a visible band at 592bp (Figure
6A, left). Figure 6B illustrates the MgCl2 optimization for the human Dlk1 methylation
probe (hDLK1mp) and a band appeared in lane 8 (1.6mM MgCl2) at 582bp. The
MgCl2 optimization for the human PWS methylation probe (hPWSmp) reveals the
best result in lane 7 (1.2mM MgCl2) showing a band at 616bp (Figure 6C, left). In
Figure 6D the MgCl2 optimization of the human OCT-4 methylation probe
(hOCT4mp) shows the best result in lane 7 (1.2mM MgCl2) by the appearance of a
band at 532bp. The MgCl2 optimization of the MAGE-A1 methylation probe (hMAGE-
A1mp), shown in Figure 6E, reveals a band in lane 7 (1.2mM MgCl2), at a length of
607bp. Figure 6F shows the design of a human endogenous retrovirus methylation
probe (hHERV(gag)mp) and reveals the best result in lane 6(1mM MgCl2) showing a
band at 574bp. The MgCl2 optimization according to the human AluJb methylation
probe (hAluJbmp) reveals a band at 411bp in lane 7 (1.2mM MgCl2) (Figure 6G).
The human sat2 methylation probe (hSat2mp), shown in Figure 6H, reveals the best
result according to MgCl2 optimization within lane 8 (1.6mM MgCl2), showing a band
at 533bp. In Figure 6I the PCR for human mitochondrial methylation probe (hMTmp)
is shown and the best result was achieved in lane 6 (0.8mM MgCl2) showing a band
at 544bp. At last, the design of a human LINE (L1P3) methylation probe (hL1P3mp)
reveals for the MgCl2 optimization a band in lane 8 (1.6mM MgCl2) at 606bp (Figure
6J). The PCR reaction was then conducted with 1.6mM MgCl2 (data not shown).
In summary, PCR for probes to 10 specific regions were successfully con-
ducted amplifying fragments of the expected length. All fragments were cut out gel
purified and cloned into the pGEM –T-Easy vector.
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Figure 6: MgCl2 and/or Betaine optimization / PCR reactions for constructing DNA blot probes
to analyze DNA methylation status of methylated regions. A-J: M= 1kb DNA ladder, the marker in
A-D and H-J was modified with Photoshop CS2, C=control (no template), for MgCl2 optimization: Be-
taine: 0.8M, Lane 1-8 (0.4/ 0.48/ 0.60/ 0.70/ 0.80/ 1.0/ 1.2/ 1.6mM MgCl2), pd= primer dimers, for Be-
taine optimization Lane 1-4 (0/ 0.4/ 0.8/ 1.2M Betaine) A: hH19mp left: MgCl2 optimization: A frag-
ment in lane 7(1.2mM MgCl2) and lane 8 (1.2mM MgCl2) is visible at 592bp in addition to primer di-
mers (pd). right: The PCR was repeated with 1.2mM MgCl2 and the bands were cut out. B: hDLK1mp
left: as in A, left: The size of the fragment is 582bp (lane8, 1.6mM MgCl2). right: The Betaine optimi-
zation was conducted with 1.6mM MgCl2, showing no effect. C: hPWSmp left: as in A, left: The size of
the fragment is 616bp. right: as in B, right (MgCl2 =1.2mM). D: hOCT4mp left: as in A, left: The size of
the fragment is 532bp (lane7, 1.2mM MgCl2); right: as in A, right (MgCl2 =1.2mM) E: hMAGEA1mp
left: as in A, left: The size of the fragment is 607bp (lane 6, 7, 8 with 1.0/ 1.2/ 1.6mM MgCl2). right: as
in B, right (MgCl2 =1.2mM) F: hHERV(gag)mp left: as in A, left: The size of the fragment is 574bp
(lane 6,7,8 with 1.0/ 1.2/ 1.6mM MgCl2). right: as in A, right: (MgCl2 =1.0mM) G: hAluJbmp left: as in
A, left:  The size of the fragment is 411bp (lane7, 1.2mM MgCl2). right: as in A, right: (MgCl2 =1.2mM)
H: hSat2mp left: as in A, left: The size of the fragment is 533bp (lane7, 8 with 1.2/ 1.6mM MgCl2);
right: as in A right: (MgCl2 =1.6mM) I: hMTmp left: as in A, left: The size of the fragment is 544bp
(lane 6, 8 with 0.8/ 1.6mM MgCl2); right: as in A, right: (MgCl2 =0.8mM) J: hL1P3mp left: as in A, left:
The size of the fragment is 606bp (lane 8 with 1. 6mM MgCl2).
31
2.1.3 Control digestion of the cloned PCR fragments
After transformation into CaCl2-competent bacteria and blue/white selection,
the insert sequence for each construct was checked by enzyme digestion (Figure
7A-J). The theoretical sequence of the vector plus insert was created in silic” with the
software Gene Constuction Kit using publically available DNA sequence and the
theoretical digestion pattern was determined.
In all cases the predicted digestion pattern, on the right for each construct, fits
to the obtained digestion pattern on the left. In Figure 7A the digestion pattern of the
cloned PCR product hH19mp, digested with Cfr421, is shown. The in silico predicted
digestion pattern indicates 3 bands 3320bp, 404bp and 120bp and all three bands
were obtained, although the band at 120bp is very faint. In the uncut control (C) lane
higher molecular bands are present. These bands are different conformations of the
uncut vector ranging from supercoild plasmids that move fast through the agarose to
an open circle confirmation that moves slower and are also seen in other gels in this
figure. In Figure 7B the digestion of the cloned hDLK1mp with RsaI is shown. Three
bands are visible at 1982bp, 1363bp and at 251bp that match the predicted pattern.
In Figure 7C the AluI digestion pattern of the hPWSmp pGEM-T-Easy construct is
shown. The in silico digestion predicts 16 bands in total, although 10 bands are of
small size and were not visible. However, the obtained digestion pattern shows a
thick band that indicates a band at 671bp as well as 655bp, a smaller band at 520bp
as well as thick, smeary band at approximately 200bp (indicated as a red dot 1) and
one at approximately 120bp (indicated as a red dot 2). The PvuII digestion pattern of
the pGEM-T-Easy vector containing the hOCT4mp product is shown in Figure 7D.
The in silico digestion pattern predicts four bands: at 2563bp, 491bp, 312bp 179bp,
which are present in the obtained digestion. The cloned hMAGE-A1mp fragment,
digested with RsaI, displays 2 bands with a size of 2207bp and 1425bp that match
the predicted bands. In Figure 7F the cloned hHERV(gag)mp was digested with
DraIII or RsaI. Similarly, on RsaI digestion produced the predicted bands at 2196
and 1313bp. Figure 7G shows the digestion the coned hAluJbmp fragment, digested
with PvuII or BstXI.  The predicted PvuII bands at 2563bp, 574bp and 289bp were
seen. Similarly, the predicted BstXI fragments at 3077bp and one at 349bp were
obtained. In Figure 7H the hSat2mp cloned fragment was digested with revealing the
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Figure 7: Restriction fragment patterns confirming cloning of correct PCR fragments into p
GEM-T-Easy  M= 1kb DNA ladder, C= Control (no enzyme), visible in different conformations ranging
from supercoild, nicked circle to multimere. The in silico predicted pattern fits in all cases to the ob-
tained digestion pattern. A: The hH19mp pGEM-T-Easy construct was digested with Cfr421. The right
side shows the in silico predicted digestion pattern with 3 bands present (3320bp, 404bp, 120bp). The
left side indicates the obtained digestion pattern with the same bands present. B: The hDLK1mp
pGEM-T-Easy construct digested with RsaI. The fragment sizes are: 1982bp, 1363bp and 251bp C:
The hPWSmp pGEM-T-Easy construct digested with AluI. The fragment sizes are: 671bp, 655bp,
520bp, 256bp, 225bp, 213bp, 117bp plus 10 more, that were not visible due to their small size. D:
The hOCT4mp pGEM-T-Easy construct digested with PvuII. The fragment sizes are: 2563bp, 491bp,
312bp, 179bp. E: The hMAGE-A1mp pGEM-T-Easy construct was digested with RsaI. The fragment
sizes are: 2207bp and 11425bp. F: The hHERV(gag)mp pGEM-T-Easy construct was digested with
DraIII or RsaI. The fragment sizes for DraIII are: 2932bp and 657bp and for RsaI: 2196bp and
1393bp. G: The hAluJbmp pGEM-T-Easy construct was digested with PvuII or BstXI. The fragment
sizes are for PvuII: 2563bp, 574bp and 298bp and for BstXI: 3077bp and 349bp. H: The hSat2mp
pGEM T-Easy construct was digested with DraIII. The fragment sizes are: 2960bp and 588bp. I: The
hMTmp pGEM-T-Easy construct was digested with HindIII and DraIII. The fragment sizes are: 3002bp
and 557bp. J: hL1P3mp pGEM-T-Easy construct: digested with BstXI. The fragment sizes are:
3200bp and 356bp.
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predicted bands at 2960bp and 588bp. In Figure 7I the hMTmp construct was di-
gested with HindIII plus DraIII. The predicted bands at 3002bp and 557bp were
seen. The last construct is shown in Figure 7J and was digested with BstXI to con-
firm that the vector contains the hL1P3mp. The predicted bands at 3200bp and
356bp were seen, although the smaller fragment at 356bp is very faint.
 To summarize up, all PCR fragments were cloned successfully into the
pGEM-T-Easy vector as shown by the predicted restriction fragments being seen.
Additionally, the inserts were sequenced confirming they were the correct sequence.
2.1.4 Probe preparation
In the next step, the constructs were digested with EcoRI to cut out and gel
purify the DNA-blot probes (Figure 8 A-K). Upon digestion with EcoRI all cloned PCR
fragments were extended in their length by 18bp due to the fact that EcoRI cuts at
the flanking edge either side of the insert in the vector. In the EcoRI digests shown in
Figure 8A-I the band at 2996bp is the vector backbone. In Figure 8A one can see the
digestion of the hH19mp pGEM-T-Easy construct with EcoRI resulting in the desired
fragment of 610bp in length. Figure 8B shows the digestion of hDLK1mp pGEM-T-
Easy construct with EcoRI resulting in the predicted fragment at 600bp. The red star
indicates an extra higher molecular weight band that maybe the uncut pGEM-T-Easy
vector. The hPWSmp pGEM-T-Easy construct digest shown in Figure 8C reveals the
expected fragment of 624bp. The hOCT4mp pGEM-T-Easy construct digest is
shown in Figure 8D. Upon digestion with EcoRI the expected band of 550bp was
seen.  The hMAGE-A1mp digestion of the pGEM-T-Easy construct with EcoRI is
shown in Figure 8E. The desired fragment was is present at 625bp. Figure 8F shows
the hHERV(gag)mp pGEM-T-Easy construct digested with EcoRI and the predicted
fragment was visible at 592bp. In Figure 8G the probe preparation of hAluJbmp is
shown. The pGEM-T-Easy construct was digested with EcoRI revealing a very faint
band at 429bp as the DNA blot probe. The EcoRI digestion of hSat2mp pGEM-T-
Easy construct is shown in Figure 8H. The predicted band was present at 551bp. In
Figure 8I the EcoRI digestion of the hMTmp pGEM-T-Easy construct is shown. The
digestion reveals a band at 562bp representing the DNA blot probe. The hL1p3mp
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pGEM-T-Easy digestion with EcoRI is illustrated in Figure 8J and confirms the pres-
ence of the DNA blot probe at a length of 625bp. The next DNA blot probe prepara-
tion was conducted for the digestion of the pE3Up plasmid with BstXI, shown in Fig-
ure 8K. This construct contains the Bx probe that detects the upstream region of the
AIRN DMR. Upon digestion with BstXI 4 fragments were present, with the fragment
at 577bp representing the DNA blot probe. Figure 8L shows the digestion of the
pEX1 construct with HindIII and BstEII for the preparation of the HB probe, that
detects an upstream region of the IGF2R CpG island. The DNA blot probe (HB) was
present at 500bp.
Figure 8: DNA blot probe preparation M=1kb DNA ladder, red asterix= uncut vector. (A-J) Digest
was conducted with EcoRI resulting in the vector backbone at 2996bp and the probe size indicated in
the respected legend. (A) hH19mp: 610bp  B: hDLK1mp: 600bp. C: hPWSmp: 634bp. D: hOCT4mp:
550bp. E: hMAGEA1mp: 625bp. F: hHERV(gag)mp: 592bp. G: hAluJbmp: 429bp; H: hSat2mp:
551bp. I: hMTmp: 562bp; J: hL1P3mp: 625bp; K: Bx(AIRN DMR) probe: pE3Up construct was di-
gested with BstXI and revealed the DNA blot probe at a length of 577bp as well as additional restric-
tion fragments at 8000bp, 1150bp and 704bp, respectively. L: HB probe: digestion of the pEX1 con-
struct was conducted with HindIII and BstEII and showed the DNA blot probe at 500bp as well as two
other fragments at approximately 3000bp.
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Taken together, all the digestions worked and the DNA blot probes at the ex-
pected length were cut out, gel purified and then used to detect the specific chromo-
somal under investigation and to analyze their methylation status.
2.2 The normal DNA methylation status of the control regions
In order to determine the normal methylation status of the regions in Table 1
in human fibroblasts (Hs-27) cells, DNA from these cells were analysed by Southern
blotting for their methylation status. For this purpose I used the DNA blot probes,
which I have designed as described above. Genomic DNA isolated from Hs-27 cells
was digested with specific enzymes. The methyl sensitive restriction enzyme HpaII
was used that recognizes a CCGG motif and can only cut at these sites when the
CG in this motif is unmethylated.  Furthermore, the isoschizomere MspI was used
which recognizes the same restriction site, but is able to cut at these sites whether
CG is methylated or unmethylated.
2.2.1 DNA methylation status of 5 imprinted clusters
Previous studies have shown that the H19 DMR is always methylated on the
paternal allele and unmethylated on the maternal allele (Bartolomei 1993, Ferguson
Smith, 1993). The normal methylation state of the H19 DMR in Hs-27 cells is shown
in Figure 9. On the left side (9B) the ethidium bromide stained gel is shown after the
digestion with BglII (Lane 1) alone or in combination with either HpaII (Lane 2) or
MspI (Lane 3). The gel was blotted on a Hybond-Nylon membrane and then hybrid-
ized with the hH19mp probe. The digestion with BglII alone results in a visible frag-
ment at 3888bp. Lane 2 displays a complex methylation pattern, which is due to the
variable methylation state of the HpaII sites in Hs-27 cells. Upon digestion with the
isoschizomere MspI three bands were visible in lane 3.  According to the digestion
map in Figure 9A, two MspI restriction sites are present inside the probe region
flanked by one BglII restriction site on the right site and additional MspI sites on the
left side. Upon double digest with BglII and MspI all CCGG sites will be cut by MspI
resulting in a fragment visible at 284bp, one at 962bp and one at 1111bp. The diges-
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tion pattern in lane 2 is not the result of the incomplete HpaII digestion as shown by
rehybridization of the membrane with the HB probe that recognizes the unmethylated
CpG island of IFG2R (Figure 9C and D). The result shows two bands for the diges-
tion with BglII and HpaII, which can be explained by three additional HpaII sites that
are present outside of the CpG island. These results show that these three HpaII
sites are in some cells unmethylated, resulting in a band recognizable at a length of
911bp, whereas in most other cells they remain methylated resulting in a visible
band at 1529bp. The MspI digestion pattern results in the 911bp fragment.
Figure 9: DNA Methylation status of the H19 DMR in Hs-27 cells; A: The Restriction map of the
H19 DMR region is shown. DNA is shown as a black bar, the H19 DMR as a yellow bar, the probe
(hH19mp) as a blue bar, methyl- in/sensitive enzymes (MspI/HpaII) are indicated by a vertical red
slash on top of the DNA and the restriction fragments upon digestion are illustrated as horizontal bars.
BglII sites are as block lines below the DNA B: left: The ethidium bromide stained gel after the diges-
tion of 10-20µg Hs-27 DNA with BglII alone (lane1) or in combination with HpaII (lane2) or MspI
(lane3). right: DNA blot: Hybridization with hH19mp results in a fragment at 3888bp with BglII alone.
In combination with HpaII a variable methylation pattern is visible or in combination with MspI three
bands are visible: at 1111bp, 962bp and 284bp. C: Same as in A except that it is the restriction map
of IGF2R CpG island. The arrow shows the direction of transcription. D: left: same ethidium bromide
stained gel as shown in B. right: DNA blot: rehybridization of the membrane in B with the HB probe.
The result upon digestion with BglII alone displays a band at 4117bp, in combination with HpaII two
bands are visible: at 1529bp and at 911bp, or in combination with MspI one fragment at 911bp is pre-
sent.
In case of the IGF2R cluster it was shown in earlier studies that the AIRN
DMR is always methylated on the maternal allele whereas the paternal allele re-
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mains always unmethylated (Smrzka, Fae et al. 1995). Figure 10 shows the normal
occurring methylation state of the AIRN DMR in Hs-27 cells. On the left side of Fig-
ure 10B the ethidium bromide stained gel after digestion with EcoRI (Lane 1) alone
or in combination with HpaII (Lane 2) or MspI (Lane 3) is shown. The gel was blotted
on a Hybond-Nylon membrane and then hybridized with the Bx probe, as shown on
the right side of in Figure 10B. The Bx probe detects a 5757bp fragment upon diges-
tion with EcoRI alone. Due to the double digestion with EcoRI and HpaII two bands
were visible, one at 5757bp and one at 2988bp. This pattern was interpreted as 50%
Figure 10: Methylation status of the AIRN DMR in Hs-27 cells; A: restriction map of the AIRN
DMR is shown. DNA is shown as a black bar, the AIRN DMR as a yellow bar and the Bx probe is
shown as a blue bar. Methyl- in/sensitive enzymes (MspI/HpaII) sites are indicated by a vertical red
slash on top of the DNA, and the resulting fragments upon digestion are illustrated as horizontal bars.
Below the DNA EcoRI sites are indicated. B: Left: ethidium bromide stained gel after the digestion of
10-20µg Hs-27 DNA with EcoRI alone (lane1), or in combination with HpaII (lane2) or MspI (lane3).
Right: DNA blot: hybridization with Bx probe resulted in a fragment at 5757bp with EcoRI alone, in
combination with HpaII two fragments appeared, one at 5757bp and one at 2988bp, while in combi-
nation with MspI one band is visible at 2988bp. An open arrowhead points towards the faint band. C:
Same as in A except that it is the restriction map of IGF2R CpG island. D: Left: the same ethidium
bromide stained gel as shown in B. Right: DNA blot: rehybridized the HB probe. The result upon di-
gestion with EcoRI alone displayed a band at 7935bp. In either case EcoRI in combination with HpaII
or MspI, resulted in a band at 684bp. Open arrowhead points towards the faint bands (7935bp and
684bp).
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methylated and 50% unmethylated, as previously described (Smrzka, Fae et al.
1995). The control digestion with MspI revealed a fragment visible at 2988bp, which
was very faint due to the unequal loading of DNA as visible in the ethidium bromide
stained gel. To assess whether the digestion pattern, obtained in lane 2 of Figure
10B, is due to the incomplete digestion of HpaII the membrane was rehybridized with
the HB probe that recognizes the unmethylated CpG island of IGF2R (Figure 10D).
This resulted in a fragment visible at 684bp for both EcoRI/HpaII and EcoRI/MspI
according to the restriction map of the IGF2R CpG island (Figure 10C). This con-
firmed that the EcoRI/HpaII digestion in 10B was complete.
It has also been reported that the DMR of DLK1, PWS and KCNQ1OT1 are
differentially methylated (Zeschnigk, Schmitz et al. 1997; Beatty, Weksberg et al.
2006; Geuns, De Temmerman et al. 2007). At these loci it is always the maternal
allele that is methylated and the paternal allele that is unmethylated.
The normal methylation status of the DLK1 DMR is shown in Figure 11B. On
the left side the ethidium bromide stained gel picture is shown after digestion with
SphI alone (Lane 1) or in combination with either HpaII (Lane 2) or MspI (Lane 3).
This gel was then blotted on a Hybond-Nylon membrane and then hybridized with
hDLK1mp as illustrated in Figure 11B on the right. The digestion with SphI alone re-
veals more than one band, an unexpected result. This might be explained by the
hDLK1mp probe cross-hybridizing with other regions. Moreover, upon the digestion
with SphI together with HpaII multiple bands are shown. This indicates a variable
methylation pattern. Lane 3 showing the digestion of SphI together with MspI shows
the three expected bands at 2638bp, 1019bp and 302bp predicted by the restriction
map in Figure 11A.
The normally occurring methyation status of the PWS DMR in Hs-27 cells is
shown in Figure 11D with the restriction map shown in Figure 11C. The DNA was
digested with EcoRI plus HpaII or MspI. The ethidium bromide gel after restriction
digest is shown in Figure 11D on the left side. This gel was then blotted onto a Hy-
bond-Nylon membrane and hybridized with hPWSmp probe. This is shown in Figure
11D on the right side. Lane 1 shows the predicted 9244p fragment upon the diges-
tion with EcoRI alone. Upon digestion with EcoRI together with HpaII a broad, but
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faint band is visible indicating a variable methylation pattern, since two HpaII sites
are present in the SNRPN DMR and multiple HpaII sites are outside of the SNRPN
DMR. The digestion with EcoRI and MspI results in the expected 5136bp fragment.
In Figure 11E the restriction map of the KCNQ1OT1 DMR is shown and in Figure
11F the normal methylation state of the KCNQ1OT1 DMR was analyzed. The ethid-
ium bromide stained gel (left) illustrates the DNA after digestion with HindIII alone
(Lane 1) or in combination with methylsensitive (Lane 2: HpaII (H), Lane 4: BstUI (B)
and Lane 5: EagI (E)) or insensitive (Lane 3: MspI (M)) restriction enzymes. After gel
blotting and hybridization with hKCNQ1OT1mp (right) the digestion with HindIII alone
showed the expected fragment at 24274bp. The digestion with HindIII together with
HpaII indicates that some of the HpaII sites are methylated (Lane 2). In comparison
to that the digestion with HindIII together with MspI (Lane 3) reveals a single frag-
ment at a length of 4065bp. An additional indication that the KCNQ1OT1 DMR is
methylated is seen upon digestion with HindIII plus BstUI, as shown in lane 4. In this
case, 4 bands are present. The longest band at 24274bp indicates that in some cells
all BstUI sites are methylated and therefore BstUI will not cut. The fragments present
at 2221bp, 5136bp and 3632bp indicated that some cells have variable methylated
BstUI sites. Additionally the digestion with EagI shows one fragment present at
24274bp and one at 5130bp.
Taken together these results revealing the normal methylation status of the
imprinted regions indicating that the H19 DMR, the AIRN DMR and the KCNQ1OT1
DMR can be used as controls for analyzing the possible loss of DNA methylation.
This is because these regions show clearly a differentially methylation pattern (AIRN
DMR), or a variable methylation pattern (H19 DMR, KCNQ1OT1 DMR). The methy-
lation status of PWS DMR and DLK1 DMR was not clearly visible with the probes
and restriction enzymes used, so these loci were not used as controls.
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Figure 11: Methylation status of the DLK1-, PWS- and KCNQ1OT1 DMR A: Restriction map of the
DLK1 DMR is shown. DNA is shown as a black bar, the DLK1 DMR as a yellow bar and the
hDLK1mp is shown as a blue bar. Methyl- in/sensitive enzymes (MspI/HpaII) sites are indicated by a
vertical black slash on top of the DNA as well as the resulting fragments upon digestion are shown as
horizontal bars. Below the DNA, enzymes are indicated which were used in combination with HpaII
and MspI, in this case SphI. B: Left: Ethidium bromide stained gel after the digestion of 10-20µg Hs-
27 DNA with SphI alone (lane1) or in combination with HpaII (lane2) or MspI (lane3). Right: DNA blot:
hybridization with hDLK1mp probe resulted in multiple fragments with SphI alone or in combination
with HpaII. SphI together with MspI revealed three visible bands at a length of 2638bp, 1019bp and
302bp, respectively. C: Same as in A except that this is the PWS DMR. D: Same as in B expect the
hPWSmp probe was used and DNA was digested with EcoRI alone or in combination with HpaII and
MspI. The observed fragments were 9244bp and 5136bp. E: Same as in A with the exception that this
is the KCNQ1OT1 DMR and HindIII plus HpaII, MspI, BstUI or EagI were used. Below the DNA EagI
is shown by the green slash and BstUI by the vertical blue slash. F: Same as in B except the
hKCNQ1OT1mp probe was used for hybridization. The hybridization resulted in one fragment at
24274bp upon digestion with HindIII alone and together with HpaII in a variable methylation pattern.
HindIII together with MspI revealed one band at 4065bp. HindIII together with BstUI resulted in 4
bands: at 24274bp, 22221bp, 5136bp and 3632bp. HindIII together with EagI resulted in two bands: at
24274bp and 5136bp.
2.2.2 DNA methylation status of MAGE-A1 and OCT-4
Besides imprinted genes there is a subset of genes, which show a repressed
transcription status associated with promoter DNA methylation. For instance, a
member of the cancer/ testis antigen family, MAGE-A1 and the stem cell transcrip-
tion factor OCT-4. For the MAGE-A1 gene, it was shown that DNA demethylation
correlates with transcriptional activity (De Smet, Lurquin et al. 1999) thus making it a
potential control for my experiment. The OCT-4 gene transcriptional start site was
shown to become methylated during differentiation (Freberg, Dahl et al. 2007). It
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should be noted that both genes presented in here lack a CpG island but are CpG
rich.
I assessed the methylation status of the MAGE-A1 and OCT-4 promoter re-
gion. In Figure 12B the DNA blot with methylsensitive restriction enzymes for MAGE-
A1 is shown. On the left side the ethidium bromide gel is presented after digestion
with NcoI alone or in addition with methylsensitive restriction enzymes (HpaII, BstUI
or EagI) and the insensitive restriction enzyme MspI. The result after blotting the gel
on a Hybond-Nylon membrane and hybridizing with hMAGEA1mp is shown on the
right side in Figure 12B. A clear band of 9677bp is visible in lane 1 upon digestion
with NcoI alone. The digestion pattern in lane 2 is the result of the double digest with
NcoI and HpaII. Here a clear band is present at 2355bp matching the unmethylated
band present in lane3 (NcoI + MspI).  In addition, two faint bands are shown at a
length of 3615bp and approximately 4500bp indicating methylated HpaII sites ac-
cording to the restriction map shown in Figure 12A. This indicates that in most Hs-27
cells the majority of HpaII sites are unmethylated, but in a minority of cells HpaII sites
are present. The digestion with NcoI together with BstUI displays 4 bands. A strong
band at 9677bp indicated that most of the BstUI sites were methylated whereas
some of them remained unmethylated and therefore additional bands appeared.
These bands were at a length of 7523bp, 4451bp, 2218bp and 1868bp, respectively,
as shown in Figure 12B on the right side. The digestion with NcoI together with EagI
revealed one band at 9677bp, thus indicating that the EagI site was methylated.
In Figure 12D the normal methylation status of the OCT-4 promoter is shown.
The left side shows the ethidium bromide gel after digestion with BamHI alone, to-
gether with HpaII or together with MspI. The gel was then blotted onto a Hybond-
Nylon membrane and hybridized with hOCT4mp. This probe analyzes the flanking
CpG sites between the conserved element 2 and 3. The result of this hybridization is
shown on the right side of Figure 12D. According to the restriction map in Figure 12C
a 8029bp fragment is expected and was seen in lane 1 upon digestion with BamHI
alone. Further, the double digest of BamHI/HpaII (lane 2) displayed a band at a
length of 1185bp which matched the only band present in the BamHI and MspI dou-
ble digest (lane 3). Above this fragment a faint band, indicated by the red arrowhead,
is visible and this correlates with some methylated HpaII sites. However
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Figure 12: Methylation status of MAGE-A1 and OCT-4 A: Restriction map of the MAGE-A1 is
shown. DNA is shown as a black bar, the transcription start site (TSS) as a yellow bar and the
hMAGEA1mp is shown as a blue bar. Methyl- in/sensitive enzymes (MspI/HpaII) sites are indicated by
a vertical red slash on top of the DNA as well as a green and blue vertical slash below the DNA. Black
vertical bar shows the NcoI restriction enzyme sites and restriction fragments are shown as horizontal
bars above the DNA. The black arrow from the TSS shows the direction of the transcription. B: Left:
Ethidium bromide stained gel after the digestion of 20µg Hs-27 DNA with NcoI alone (lane1), in com-
bination with HpaII (lane 2), MspI (lane 3), BstUI (lane 4) or EagI (lane 5). Right: DNA blot hybridiza-
tion with hMAGEA1mp probe resulted in a 9622bp band for the digestion with NcoI alone. NcoI to-
gether with HpaII resulted in a strong 2355bp band and faint bands at 3615bp and 4500bp (lane 2). A
digestion with NcoI and MspI showed only the 2355bp band. Digestion EagI + NcoI revealed a single
fragment at 9677bp. C: Same as in A with the exception that this is the OCT4 promoter region. CR1-4
indicates conserved regions 1-4. BamHI is indicated below the DNA. Digestion with BamHI alone
reveales a band at 8029bp and together with MspI at 1185bp. D: Same as in B with the exception of
the used enzymes and the obtained restriction fragments. used enzymes: The digestion with BamHI
alone reveled a fragment at 8029bp (lane1), BamHI together with HpaII (lane2) resulted in a fragment
at 1185bp and a faint band above (indicted by the red arrow head). The digestion with BamHI to-
gether with MspI revealed a fragment at 1185bp.
it appears that most of the CpG sites in the majority of cells remain unmethylated at
CR2 and CR3.
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Concluding, both the MAGE-A1 and OCT-4 promoter regions, by DNA blot
were not clearly methylated in Hs-27 cells as analyzed with the probes and restric-
tion enzymes described. Therefore these regions were not included as controls in
further experiments.
2.2.3 DNA methylation status of repetitive elements
As pointed out in the introduction DNA methylation is also involved in pre-
venting the transposition of transposable elements (Bourc'his and Bestor 2004). It is
known, that repetitive elements like SINEs, LINEs and a Satellite repeats containing
a large fraction of the methylated CpG sites throughout the human genome
(Weisenberger, Campan et al. 2005). These studies suggest that the methylation
status of repetitive elements could also be used as controls in my experiment. Firstly,
I assessed their normal methylation state in Hs-27 cells as shown in Figure 13. On
the left side of Figure 13A the ethidium bromide stained gel after digestion with HpaII
(methylation sensitive-lane 1) and MspI (methylation insensitive-lane 2) is shown.
The gel was then blotted onto a Hybond-Nylon membrane and hybridized with
hL1P3mp that detects LINE repeats as is shown on the right. The results indicated
that most of the CpG sites were methylated, since a higher molecular fragment was
present in lane 1 upon the digestion with HpaII (black arrow) compared with the MspI
digestion (lane 2). Additionally, smaller fragments were present in lane 1 with fainter
signal intensity. This indicated that in some cells some of the LINE HpaII sites were
not methylated whereas the majority of the CpG dinucleotides were methylated or
that some LINE repeats were not methylated but the majority were. In lane 2 the di-
gestion with MspI revealed a shift from a higher molecular fragment (closed arrow, in
lane 1) to a lower molecular sized band (open arrow). This shift was also visible on
the ethidium bromide gel. Since MspI is methylation insensitive also smaller sized
fragments were visible at a higher intensity as well as an additional band appears
that was not present in the HpaII lane (green arrow).
The satellite 2 repeats are located in the pericentromeric region and are highly
associated with DNA methylation, as published earlier (Weisenberger, Campan et al.
2005). Figure 13B examines the normal methylation state of satellite 2 repeat in Hs-
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27 cells. On the left side of Figure 13B the ethidium bromide stained gel is shown
after digestion with HpaII (methylation sensitive-lane 1) or MspI (methylation insensi-
tive-lane 2). The comparison of the HpaII digestion and MspI digestion shows al-
ready in the ethidium bromide gel a shift from a higher band to a lower molecular
band as may also seen in Figure 13A. This gel was blotted on a Hybond-Nylon
membrane and hybridized with hSat2mp to detect Satellite 2 repeats as shown on
the right side of Figure 13B (after 2 hours of exposure). If we consider the HpaII di-
gestion in lane 1 a higher molecular band was present as indicated by the black ar-
row and no defined additional bands appeared at a smaller size (although there was
a smear over a large size range). This indicated that most HpaII sites were methy-
lated. However, upon the digestion with MspI (lane 2) the higher molecular band
shifted towards a lower molecular size as shown by the open arrows. In addition 3
other bands were present at a smaller size (green arrows), albeit at a very low inten-
sity.
The normal methylation status of the AluJb element that belongs to the SINE
family is illustrated in Figure 13C. On the left side the ethidium bromide gel is present
after the digestion of DNA with HpaII (lane 1) and MspI (lane 2). The ethidium bro-
mide gel indicated the methylation sensitive HpaII gave larger digestion fragments
than the methylation insensitive MspI that both recognize the same restriction site.
After DNA blotting on a Hybond-Nylon membrane and hybridization with hAluJb in
the HpaII digestion (lane1) the black arrow indicated a higher molecular weight
smear compared to the MspI digestion (lane 2) (Figure 13C, right side). This indi-
cated that most of the HpaII sites are methylated in AluJb Sine repeats in Hs-27
cells.
Finally, I analyzed the methylation state of long terminal repeats (5’LTR) from
human endogenous retrovirus (HERV). It was published previously that retroviral
elements are highly methylated in normal cells (Walsh, Chaillet et al. 1998), but hy-
pomethylated in cancer cells (Menendez, Benigno et al. 2004). In Figure 13E the
methylation state of 5’LTR elements in Hs-27 cells is shown. On the left side the
ethidium bromide gel is depicted after the digestion with EcoRI alone or in combina-
tion with HpaII or MspI. The gel was then blotted onto a Hybond-Nylon membrane
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and hybridized with hHERV(gag)mp. The results are shown in Figure 13E on the
right side. The digestion with EcoRI alone shows multiple bands.
This was expected since the DNA blot probe was designed for covering a re-
petitive region and therefore recognizes not only one HERV. Nevertheless, the di-
gestion pattern obtained upon double digest (EcoRI+ HpaII) showed 3 broad thick
bands. The longest band was approximately 5000bp, a second at 3000bp and the
smallest band at approximately 1200bp. Overall this was an indication that the 5’LTR
element of HERVs were highly methylated, since in the MspI digestion in lane 3 the
5000bp and 3000bp largely disappeared at a remarkable level. However, smaller
bands with a strong intensity appeared instead.
Figure 13: Methylation status of repetitive elements: LINE (L1P3), Satellite2, SINE (AluJb) and
of HERVs: In all digestions HpaII (methyl-sensitive) or MspI (methyl- insensitive) was used. HERV
was digested in combination with EcoRI. A: LINE (L1P3): Left: ethidium bromide stained gel. Right:
DNA blot hybridized with hAluJbmp. Black arrow shows higher molecular band. Open arrow shows
smaller molecular band and the green arrow shows an additional band that is not present in the HpaII
digestion. B: same as in A, except it was hybridized with hSat2mp. C: same as in A, except it was
hybridized with hAluJbmp. D: Restriction map of a HERV: black bar: DNA, red bar: 5’LTR or 3’LTR,
yellow bar: gag region, orange bar: pol region and green bar: env region. Methylsensitive and
methylinsensitive enzymes (HpaII and MspI) are shown as vertical bars above the DNA. A 5136bp
restriction fragment is shown as a horizontal bar, below the DNA the probe is shown as a blue bar
covering the gag region. Flanking restriction enzyme EcoRI E: same as in A, except: enzymes as
described in D. DNA blot hybridized with hHERV(gag)mp.
In summary, the methylation status of L1P3 elements and the 5’LTR of
HERVs could serve as controls in my further experiments because a clear methyla-
tion pattern was observed. On the contrary, the methylation status observed for the
AluJb and Satellite2 repeat was excluded from further experiments. Although, it was
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shown that these elements were methylated, the difference in the Southern blot
banding pattern was not so dramatic as for L1P3 and the 5’ LTR of HERV and
therefore it would be difficult to quantify subtle changes in the DNA methylation
status.
2.3 DAC Treatment of Hs-27 cells and analysis of Loss of Methylation
Previous studies have shown that 5-aza-2’deoxycytidine (DAC) can induce
differentiation (Creusot, Acs et al. 1982), cytotoxicity (Juttermann, Li et al. 1994),
DNA demethylation and reactivation of silenced genes (Jones and Taylor 1980) at
micro-molar concentrations. My initial experiments focused on determining the opti-
mal DAC dose in Hs-27 cells that demethylated DNA but had low enough cytotoxicity
to allow the cells to still proliferate.
2.3.1 Continuous DAC treatment over 5 days (L1P3)
The first DAC treatment regime that I used was continuous treatment. I
treated the cells in total for 5 days, changed the media every day as well as with new
drug supply. I used a DAC concentration range from 0-20µM based on previous
studies (Juttermann, Li et al. 1994).  In Figure 14A the ethidium bromide stained gel
is shown after the digestion with HpaII or MspI. In the ethidium bromide gel the
methylation sensitive HpaII digest from the control untreated sample appeared
slightly larger than the treated samples. The gel was then blotted on a Hybond-Nylon
membrane and hybridized with hL1P3mp, as shown in Figure 14B. The result
showed the appearance of small molecular weight bands in the treated samples
upon digestion with HpaII (Figure 14B green box and 9C the blow up of the green
box), although these bands are only visible at 0.05-0.5µM. At higher concentrations
this faint band is not visible anymore. DNA loading was assessed upon the rehy-
bridization of the membrane with hMTmp. The red box marks the 1.2kb fragment,
which was used for quantification of the signal intensity between HpaII and MspI
bands. The quantification is shown in Figure 14D. A slight increase at middle con-
centration range was detectable.
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Figure 14: Continuous DAC treatment of Hs-27 cells for 5 days (DNA preparation 12.11.08) For
each concentration 3 x 105 cells were seeded in a 10cm dish and the media and drug supply was
changed every 24 hours. The concentration range: 0.05, 0.1, 0.2, 0.5, 0.7, 1.0, 2.0, 3.0, 10, 20 µM is
indicated on the top in A and B. A: Ethidium bromide stained gel after DNA digestion with HpaII or
MspI. A shift from a higher molecular fragment (C) to a smaller fragment (HpaII lanes in all treated
samples) was observed. B: Top: DNA blot of hybridized with hL1P3mp, exposure time: 4days. The red
box indicates the HpaII and MspI band that were consulted for quantification. The green box indicates
a slight gain of a band in the HpaII lanes of concentration 0.05-0.2µM. Bottom: rehybridization of the
membrane with hMTmp: this showed the unequal loading. C: Blow up of the green box shown in B. D:
Quantification of the HpaII and MspI bands from B; no obvious change is detactable.
2.3.2 Viability assay of DAC treated Hs-27 cells
As mentioned above, DAC is not only a demethylation agent but can also in-
duce cytotoxicity which occurs after G1 or G2 arrest initiated through the p53 path-
way(Karpf, Moore et al. 2001; Zhu, Hileman et al. 2004; Palii, Van Emburgh et al.
2008). Therefore, I examined the effect of DAC on the viability of Hs-27 cells. The
cells were treated with a dose ranging from 0-20µM. Every, second day the cell
48
number was counted for each concentration. The results are shown in Figure 15.
After two days there was no obvious affect on the cell viability (Figure 15A). After 4
days, cell viability slowly declined with increasing concentrations of DAC (Figure
15B). The decline was first apparent at 0.5µM DAC and was greater at 20µM (Figure
15B). After 6 days treatment a decline in cell viability was visible at even the lowest
DAC concentration (Figure 15C). The first decline was visible between a dose of 0 -
0.1µM, illustrated by a drop from 90% to ~75% viability. The second decline was
present at concentrations between 0.1-20µM as a drop from 75% to ~65% viability.
Although the experiment was conducted in one technical replica, the results indicate
in here that DAC treatment has a negative effect on the viability of the cells with in-
creasing concentration.
Figure 15: Viability of continuous DAC treated Hs-27 cells: for each concentration range 3 x 105 /
10cm dish were seeded, treated and then counted after 2, 4 and 6 days. The experiment was con-
ducted in one technical replica. X-axis indicates the concentration range from 0-20µM and the y-axis
indicates the viability in percent A: Hs-27 cells counted after 2 days B: counted after 4 days C:
counted after 6 days
2.3.3 Continuous DAC treatment over 5 days (H19 DMR)
To determine whether the effect of no obvious loss of DNA methylation was
restricted to repetitive elements as shown in Figure 14, I examined with the same
treatment strategy the effect on a single copy gene. I repeated the DAC treatment
experiment, since I was unable to isolate enough DNA from the initial experiment
presented in Figure 14. The results presented in Figure 16 show the analysis of the
DNA methylation status of the H19 gene after DAC treatment. The ethidium bromide
stained gel (Figure 16A) showed no indication of a loss of DNA methylation in con-
trast to the ethidium bromide gel for the L1P3 repeat, where a slight shift of the HpaII
lane compared to the MspI lane was visible (Figure 14). A slight decrease in the
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amount of loaded DNA is visible already at a concentration of 0.1, which became
more apparent with increasing concentrations of DAC (Figure 16A). The hybridiza-
tion of the membrane with the hH19mp is shown in Figure 16C after a 24hr exposure
and in Figure 16D after a 4day exposure. In the control lane a 3888bp band was
present upon the digestion with BglII alone as expected according to the restriction
map in Figure 16B. The double digestion with BglII and HpaII revealed a complex
methylation pattern. Lane 3 showed the digestion with BglII together with MspI and
resulted in 3 visible fragments at 1111bp, at 962bp and at 284bp. The double diges-
tion with BglII and HpaII in the treated samples with DAC concentrations ranging
Figure 16: Continuous DAC treatment of Hs-27 cells for 5 days: (DNA preparation 18.11.08): A:
Ethidium bromide stained gel after digestion with HpaII or MspI; Ma= Marker; C= untreated control.
The concentration range 0.05-20µM is shown above the gel.  A decrease in the loading of DNA was
visible with increasing DAC concentrations. B Restriction map of the H19 DMR region as described
earlier (Figure 9). C: DNA blot hybridized with hH19mp after 24 hr exposure. In C (BglII-): 3888bp
fragment was visible, (+HpaII): showed a complex methylation pattern, (+MspI): 1111bp, 962bp and
284bp fragments were visible: Higher molecular bands in (+HpaII) of the treated samples decreased
in intensity and a band at 962bp appeared. Red box indicates the bands used for the quantification.
D: same as in C with the exception of 4 day exposure. E: Quantification of the HpaII/ MspI ratio of
bands shown in D on the right. X-axis indicates the DAC concentrations and the y-axis indicates the
HpaII/MspI ratio. An increase of the signal intensity of the 962bp fragment in the BglII/HpaII lane with
increasing DAC concentrations was detected.
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from 0.05 until 2.0µM clearly showed a fragment present at a length of 962bp that
was absent in the control (lane HpaII (H)), indicating a loss of methylation. The
quantification was conducted between the gained BglII/HpaII fragment and the
BglII/MspI fragment, indicated in Figure 16D by the red box. The results in Figure
16E revealed a slight increase in signal intensity for the 962bp fragment in the
BglII/HpaII lane.
2.3.4 Continuous DAC Treatment over 9 days (L1P3)
Since there was no obvious loss of DNA methylation for L1P3 (Figure 14), and
only a partial loss of DNA methylation for the H19 DMR (Figure 16), I therefore ex-
tended the durat ion of  the t reatment f rom 5 to 9 days.  Accordingly,  I
Figure 17: Continuous DAC treatment of Hs-27 cells for 9 days - L1P3 under investiga-
tion: (DNA preparation 27.11.08): For each concentration 3 x 105 cells were seeded in a
10cm dish and the media and drug supply was changed every 24 hours over 9 days. The con-
centrations used were 0.05, 0.1, 0.2, 0.5, 0.7, 2.0, 3.0, 10, 20 µM as indicated on the top of A,
B, C; Ma=1kb DNA ladder; C=untreated control A: Ethidium bromide stained gel after DNA
digestion with HpaII or MspI. Unequal loading of DNA was visible. B: DNA blot of hybridized
with hL1P3mp: exposure time: 18 hours C: Exposure time 4 days. Red box indicates the HpaII
bands that were consulted for quantification with comparison to a higher molecular HpaII band
(green boxes); arrow= gain of a band; D: Top: blow up of the gained 200bp band (red box)
which were quantified upon comparison with a higher molecular weight fragment, 1200bp
(green box). Bottom: In the quantification a slight intensity increase for the 200bp band is de-
tectable.
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treated the cells in a continuous manner for 9 days and analyzed the DNA methyla-
tion status of the L1P3 repeat (Figure 17). In Figure 17A the ethidium bromide
stained gel is shown after the digestion with HpaII or MspI. The gel picture indicated
that DNA loading was unequal. Moreover, a slight shift from a higher molecular size
in the control HpaII lane to a smaller molecular size in the treated samples was visi-
ble. The gel was then blotted on a Hybond-Nylon membrane and hybridized with
hL1P3mp, as shown in Figure 17B and C. After 18 hours of exposure (17B) the sig-
nals appeared at a strong intensity in the control lane and to a lesser intensity in the
treated samples, although no noticeable change in the DNA methylation pattern was
detected. After 4 days exposure a faint band appeared at a small size (~ 250bp)
matching a MspI band (see arrow, Figure 17C). This band was slightly present in the
control digestion with HpaII, and appeared in the 0.05-0.7µM DAC treated cells
stronger, becoming fainter with increasing DAC concentrations and disappeared af-
ter 2µM. This band was quantified in comparison with a higher molecular band, illus-
trated by the green boxes. The result of this quantification is illustrated in Figure 17D.
The gain of this band was more obvious in the blow up. The quantification revealed a
relative increase in the intensity of the smaller molecular fragment, with increasing
DAC concentrations up until 0.7µM interpreted due to unequal DNA loading. These
results showing the gain of a small molecular weight fragment were similar to that
shown in Hs-27 cells treated for 5 days with DAC (Figure 14). In summary results
indicated that although some CpG sites were demethylated, the majority of the CpG
sites remain methylated. Therefore, no obvious loss in the DNA methylation pattern
was detected.
2.3.5 Non-continuouse DAC treatment over 9 days (L1P3 and HERV)
DAC induces cytotoxicity, upon the trapping of the DNMT1 (Juttermann, Li et
al. 1994) and activation of the p53 pathway (Karpf, Moore et al. 2001), as mentioned
above. Therefore, in order to minimize the cytotoxicity effect (shown in Figure 15) I
tested non-continuous DAC treatment. I treated the cells once every third day over 9
days. This gave the cells more time to recover from the cytotoxic stress and to repli-
cate which is necessary for DAC induced DNA. The continuous treatment at low and
at high concentrations could lead to a high level of DAC in the cells not allowing DNA
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damage to be efficiently repaired and inducing apoptosis. With non-continuous
treatment every three days, DAC levels should decline between treatments because
the half-life is 21 hours at 37°C at pH 7.0 (Stresemann and Lyko 2008).
In this case I treated the cells over 9 days and the result of the DNA digestion
with HpaII and MspI is shown in Figure 18A. From the ethidium bromide stained gel
it appears that the amount of loaded DNA is unequal, compared between the sam-
ples (Figure 18A). After hybridization with the hL1P3mp probe the results show this
more clearly (Figure 18B and C). In addition it appears that the MspI digestion from
0.5, 2.0, 10 and 50µM is incomplete because a thick higher molecular band is pre-
sent, which the untreated control lacks (Figure 18B and C). Nevertheless, in the
control sample the HpaII digestion compared to the MspI digestion revealed that
most of the CpG sites were methylated and therefore signal intensity in the HpaII
digestion was lower for the smaller sized fragments.  On the contrary, if the HpaII
and MspI lanes from the 1.0µM DAC treatment were compared to each other it ap-
peared that some of the CpG sites were demethylated. For this purpose the MspI
lanes and HpaII lanes, that are illustrated in Figure 18D by the red box, were quanti-
fied and compared to each other within the control as well as within each concentra-
tion from 0.1-10µM. This reveals, apart from unequal loading, that a partial decrease
of DNA methylation is visible if e.g. upon comparing the quantification of the 1.0µM
lane to the control lane.
The DNA methylation of the 5’ LTR of human endogenous retrovirus (HERV)
after non-continuous DAC treatment is shown in Figure 19. I digested the DAC
treated DNA with EcoRI together with HpaII or MspI.  The ethidium bromide stained
gel indicated unequal loading. The gel was blotted on a Hybond-Nylon membrane
and hybridized with the hHERV(gag)mp probe. The results are shown in Figure 19C
and D after 24 hours or 48 hours of exposure, respectively. The DNA blot results
showed firstly, that the amount of loaded DNA was unequal between the samples,
although loading appeared equal between the HpaII and MspI lanes within a sample.
This made the quantification of HpaII compared to MspI lanes possible. The red box
showed the bands of the HpaII and MspI lanes and indicated that the HpaII band
increased in intensity compared to the control. The quantification of these bands
made this clearer. These results must be cautiously interpreted due to the unequal
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DNA loading, but the treated samples appeared to show a partial decrease in the
DNA methylation pattern, which appeared to be constant from 0.1 to 3µM DAC.
In summary, the results from the non-continuous (pulse) treatment suggested
a partial loss of DNA methylation had occurred at L1P3 and HERV repetitive ele-
ments, but this finding was confounded by unequal DNA loading. To try to determine
if loss of DNA methylation really can be induced by non-continuous DAC treatment I
next examined the DNA methylation status of non-repetitive elements.
Figure 18: non- continuous treatment (pulse) DAC treatment of Hs-27 cells for 9 days- L1P3
under investigation (DNA preparation 11.12.09): for each concentration 3 x 105 cells were seeded
in a 10cm dish. The media and drug supply was changed every 72 hours over 9 days.
The concentration range was 0.1, 0.2, 0.5, 0.7, 1.0, 2.0, 3.0, 10, 20 and 50µM as indicated on the top
of A, B, C; Ma= 1kb DNA ladder; C= untreated control A: ethidium bromide stained gel after DNA
digestion with HpaII or MspI. Unequal loading of DNA was visible. B: DNA blot hybridized with
hL1P3mp and exposed for 24 hours. Red box indicated the bands in HpaII and MspI which were con-
sulted for quantification; C: same as in B except: exposure is 7 days. D: The bands that were con-
sulted for quantification are shown by the red box. The MspI band intensity was divided by the HpaII
band intensity. X-axis indicates the DAC concentrations; y-axis shows the average of MspI to HpaII. A
partial loss of DNA methylation was seen compared to the control.
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Figure 19: Pulse DAC treatment of Hs-27 cells for 9 days – HERV is under investigation (DNA
preparation 11.12.09): For each concentration 3 x 105 cells were seeded in a 15cm dish, the media
and drug supply was changed every 72 hours over 9 days. The concentration range was 0.1, 0.5, 0.7,
0.2, 1.0, 2.0, 3.0µM as indicated on the top of A, C, D. Ma= 1kb DNA ladder; C= untreated control A:
DNA was digested with EcoRI together with HpaII or MspI. Unequal DNA loading was visible in the
ethidium bromide stained gel. B: Restriction map of HERV as described earlier in Figure 13. C: DNA
blot hybridized with hHERV(gag)mp and exposed for 24 hours. The red box shows the HpaII and
MspI band that were consulted for the quantification. D: Same as in C with the exception that the ex-
posure was 48 hours. E: Quantification by ImageJ of the bands from the red box in C.
2.3.6 Non-continuous DAC treatment over 9 days (H19 and AIRN DMR)
In order to examine the effect of 9 days non-continuous DAC treatment on the
DNA methylation state of the single copy H19 and AIRN DMR, I used the 3 highest
concentrations (1, 2, 3 µM DAC) from which previous experiments compared to un-
treated control cells. Accordingly, I treated the cells in the same way as described
above. Firstly, I looked at the proliferation of the cells and pictured them. Figure 20
shows the cells under the control conditions as well as under the conditions with 1, 2,
3µM non- continuous DAC treatment, respectively. From these results, it was visible
that the control had a higher cell density than the treated samples. Furthermore,
between the treated sampled there seems to be a decline in the density from 1µM to
2 and 3µM.
55
The DNA from these cells was isolated for the digestion with BglII together
with MspI or HpaII. The ethidium bromide stained gel of the three replicas showed no
obvious evidence of the unequal loading of DNA between the treated samples, but
compared to the DAC treatments the control HpaII digestion appeared to have more
DNA loaded (Figure 21A). Indeed, after DNA blotting and the hybridization with
hH19mp this became more apparent (Figure 21C). In all of the three replicas the
signals in the treated samples were less intense compared to the control. Neverthe-
less, if one considers the control HpaII digests no 962bp fragment matching the MspI
band was visible in all three replicas. This fragment only appeared after DAC treat-
ment. Despite the unequal loading, this can be cautiously interpreted as a partial loss
of DNA methylation. Moreover, the higher molecular fragments that present in the
control HpaII digestion also disappeared in the treated samples. This might be on the
one hand due to the unequal loading and on the other hand due to a partial loss of
DNA methylation indicated by the fact that a 962bp fragment was gained. The quan-
tification of the 962bp fragment between the HpaII and MspI lane within each sample
was conducted with the ImageJ program and the results are shown in Figure 21D.
These results do not show as great a difference between the control and the treated
samples as seen by visual inspection perhaps due to background signals on the
membrane.
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Figure 20: Proliferation of Hs-27 cells after 9 days of pulse treatment: Cells were treated under
the same conditions as described in Figure 19 and were photographed. The experiment was con-
ducted in three technical replica A: Technical replica 1: B: Technical replica 2 D: Technical replica 3.
A decline on cell density was visible between the control and the treated cells as well as a decline in
cell density between the treated samples with increasing DAC concentration.
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Figure 21: DNA methylation status of the H19 DMR in Hs-27 cells after 9 days of pulse DAC
treatment (DNA preparation: 25.01.09): For each concentration 3 x 105 cells were seeded in a 15cm
dish and the media and drug supply was changed every 72 hours over 9 days. The concentration
range was 1.0, 2.0, 3.0µM as indicated on the top of A, C, D; Ma= 1kb DNA ladder; C= untreated
control A: Ethidium bromide stained gel of three technical replicas digested with BglII plus MspI or
HpaII. Unequal DNA loading was visible. B: Restriction map of the H19 DMR region as described
earlier in Figure 9. C: DNA blot of 3 technical replicas hybridized with hH19mp. Replica 1 and 2: con-
trol MspI lane 2 fragments are visible, one at 1111bp and one at 962bp. Electrophoresis was con-
ducted for 6V/cm (5-6 hours) therefore the 284bp fragment was not detectable anymore in contrast to
technical replica 3. In all replicas the loading of the DNA was unequal, although in the HpaII lanes
from 1-3µM a gain of the 962bp fragment was detected. D: Quantification (ImageJ) of the 962bp band
(shown by the red box in C): for each sample the HpaII and MspI lane were compared to each other.
Next the methylation status of the AIRN DMR was analyzed in the untreated
control and the treated samples (Figure 22). The ethidium bromide stained gel indi-
cated more DNA was loaded in the control HpaII lane compared to the treated sam-
ples. This was visible in all three replicas Figure 22A. The effect became more ap-
parent after the hybridization of the membrane with the Bx probe. The untreated
control digestion with EcoRI and MspI revealed one band present at 2988bp. The
digestion of EcoRI together with HpaII resulted in fragment present at 5757bp and
one at 2988bp. These bands were visible from replica 1 to replica 3. In the treated
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samples only the 2988bp fragment was visible, although it was very faint. In replica
three the 5757bp fragment was also visible but very faint. The unequal DNA loading
and faint bands in the treated samples makes interpretation of this data difficult.
However, there were tentative indications that at least a partial loss of the DNA
methylation pattern, in DAC treated samples had occurred. This was due to the fact
that for example the 2988bp fragment in the HpaII lane of the 1µM sample in replica
3 appears to be stronger than the 5757bp fragment in the same lane. In comparison,
in the untreated control, HpaII digestion, the fragments (5757bp and 2988bp) appear
to have similar same intensity.
Figure 22: DNA methylation status of the AIRN DMR in Hs-27 cells after 9 days of non-
continuous (pulse) DAC treatment (DNA preparation date: 25.01.09): Experimental procedure
conducted as described in Figure 21. A: Ethidium bromide stained gel of the three replicas was visible
after the digestion with EcoRI together with HpaII or MspI. Unequal loading was visible in comparison
between the untreated control sample and the treated samples.  B: Restriction map of the AIRN DMR
as describe in Figure 10. C: DNA blot after 1 week exposure: The visible fragments are at 5757bp
and 2988bp according to the restriction map in B. Signals of the treated samples are low in intensity
due to unequal DNA loading.
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Taken together, these results showed no obvious loss of the DNA methylation
pattern, although it seems at least a partial loss of DNA methylation was achieved for
the H19 DMR since a gain of a band was visible. This interpretation has to be taken
with care because the DNA loading was unequal.
2.4 Expression analysis
2.4.1 qPCR analysis of the H19 ncRNA and MAGE-A1 gene
As no dramatic loss of DNA methylation was detectable by Southern blot
analysis, the effect of DAC upon the induction of gene expression of the MAGE-A1
gene and the H19 ncRNA was assessed in addition. The MAGE-A1 gene is not ex-
pressed in somatic cells but expressed in a variety of tumors as well as in the testis
of males (Simpson, Caballero et al. 2005). Moreover, the transcriptional repression
was shown to be associated with CpG methylation of the transcriptional start site (De
Smet, Lurquin et al. 1999). The H19 ncRNA shows a differential expression pattern,
as described previously. Previous studies have shown that the expression of the H19
ncRNA and MAGE-A1 gene is induced upon DAC treatment (De Smet, Lurquin et al.
1999; Lynch, Tycko et al. 2002). To assess this in Hs-27 cells I performed qPCR
assys for these two genes. Figure 23A shows the induction of the H19 ncRNA upon
normalization to the ribosomal large protein A0 (RPLPO) and illustrates that H19
ncRNA is induced upon treatment with DAC. The induction is between 10-100 fold.
The result using GAPDH (TaqMan assay) for normalization showed an induction of
5-25 fold (Figure 23C). Note the large difference in the technical replicas for H19. In
addition, the expression of the MAGE-A1 gene was induced to a 15- fold level using
RPLPO for normalization and a 5-10 fold level using GAPDH for normalization. The
induction of the MAGE-A1 expression compared to the H19 ncRNA was more con-
stant at different DAC treatment concentrations. Therefore, the expression of the
MAGE-A1 gene showed no concentration dependent induction as was visible in the
normalization to RPLPO as well as to GAPDH.
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Figure 23: Expression levels of the MAGE-A1 gene and the H19 ncRNA of DAC treated Hs-27
cells: (RNA preparation day 25.01.09). qPCR of the H19 ncRNA and the MAGE-A1 gene normalized
to RPLPO (A, B) in a SYBR green assay or to GAPDH (C,D) in a TaqMan assay. The assay was con-
ducted in 3 technical replicas and the control was set to 1. The x-axis showed the DAC concentration
range. The y-axis gives the fold induction.   Both assays reveal an induction of the H19 ncRNA and
the MAGE-A1 gene
2.4.2 RNA-expression tiling array
The effect of DAC on macro ncRNA expression was examined by using a
NimbleGen custom tiling array. The HIRTA (Human Imprinted Tiling Array) (prepared
by Irena Vlatkovic, a Ph.D. student in the lab) chip covers by 26 imprinted regions in
human. Most of these regions are roughly 1MB in length. After the identification of
repetitive sequences with the repeat masker, single copy regions were covered with
50bp oligo probes per 100bp.
In Figure 24 I show the expression of the H19 ncRNA in WT Hs-27 cells and
DAC treated cells. In WT Hs-27 cells the H19 ncRNA is not expressed, However,
upon treatment with 1µM DAC the expression of H19 is induced (see Figure 24A and
in the blow up of 24B).
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Figure 24: H19 ncRNA expression was examined using HIRTA. RNA preparation day of DAC
treated Hs-27 cells: 25.01.09. The y-axis displays the log2 ratio of cDNA normalized to genomic Hs-
27 DNA. The x-axis displays the genomic position in the human genome. CpG islands are shown as
green bars and miRNAs are in red. A: Custom tracks loaded onto the USCS browser display Hs-27
WT cells and 1µM DAC treated Hs-27 cells. B: Blow up of the H19 ncRNA from A. The results show
that H19 ncRNA expression is induced upon 1µM DAC treatment (unpublished data from Irena
Vlatkovic)
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3. Discussion
It is known that DNA methylation in imprinted regions can control the expres-
sion of macro ncRNAs (Seidl, Stricker et al. 2006). To address the question if all
macro ncRNAs in human of imprinted regions are regulated by DNA methylation it is
necessary to demethylate the genomic sequence. A DNA demethylation effect in
human is provided by using the DNA methyltransferase inhibitor, Decitabine. There-
fore, this thesis illustrates, as a basis for further studies, the effect of Decitabine, on
DNA methylation (Oki, Aoki et al. 2007). The results presented here indicate, DAC
treatment induced a very slight loss of DNA methylation at some loci as well as the
induction of gene expression, in particular the H19 ncRNA and the MAGE-A1 gene.
3.1 PCR reactions and Cloning
In order to test the DNA demethylation effect of DAC I designed 10 DNA blot
probes using PCR (Figure 6). For each of them I conducted MgCl2 concentration op-
timization in order to obtain a product. The reason for this is that MgCl2 has an influ-
ence on all steps in the PCR: denaturation, annealing, product specificity, occur-
rence of primer dimers and the activity of the TaqPol. The optimal MgCl2 concentra-
tion for my PCR reactions was in a range from 0.8 to 1.6mM. Moreover, I conducted
for the hDLK1mp (Figure 6B), hPWSmp (Figure 6C) and hMAGE-A1mp (Figure 6E)
probe PCRs, an optimization reaction for Betaine, to achieve a better result. Betaine
has the capability to enhance the substrate specificity as well as the enhancement of
amplification of GC rich regions. However, in these results Betaine did not improve
PCR yield and specificity when the optimimal MgCl2 concentration was used. There-
fore optimization was sufficient to PCR amplify the probes in this case, but with more
difficult PCRs, Betaine optimization may be useful.
There were some difficulties PCR amplifying repetitive LINE (L1P3) and SINE
(AluJb) elements. I was unable to PCR amplify a LINE element which had been pre-
viously published as being methylated (Weisenberger, Campan et al. 2005). A study
by Bourc’his et al (2004) analyzed the DNA methylation state of a LINE repeat
(5’UTR) in mouse. Therefore, I used this sequence to BLAST against the human ge-
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nome and detected a homologous LINE repeat on chromosome 9. Accordingly, I
designed a set of PCR primers located in the 5’UTR, and this LINE was then able to
PCR amplify it (Figure 6J).
In case of the SINE repeat I used a different approach. MY first set of primers
designed against SINE (AluJb) repeats failed to amplify a product using Hs-27 ge-
nomic DNA or a BAC template. Therefore, I next identified a group of Alu repeats on
the BAC2358 template and designed a new set of primers. The forward primer was
flanking a single copy region and the reverse primer was designed to a repetitive
region. Using the BAC2358 template I was able to PCR amplify the Alu repeat (Fig-
ure 1G).
Cloning of the probe templates into pGEM-T-Easy was successfully con-
ducted according to the manufacturer’s protocol.  For the Maxi Prep procedure I
used for the purification steps either the protocol “DNA purification by DNA Centrifu-
gation” or “DNA purification by DNA Vacuum”. DNA centrifugation technique was
sufficient for most of the constructs, but for some of the constructs it failed to obtain a
high enough yield. Thereafter, I used the protocol for the purification according to the
vacuum procedure. A possible explanation for the better yield of the Vacuum proce-
dure maxiprep might be that an additional centrifugation step after the neutralization
procedure collecting the cell debris and preventing the purification column of being
overloaded. An additional advantage of the vacuum purification protocol is that re-
quires less time than the centrifugation maxiprep protocol.
In summary, the PCR reactions worked after MgCl2 optimization, while Be-
taine optimization showed no effect. Moreover the cloning and maxiprep of DNA was
successful once the optimal method was chosen. In this way I cloned 10 DNA blot
probe templates for analyzing a possible loss in DNA methylation upon DAC treat-
ment of Hs-27 cells.
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3.2 Treatment strategies
The first aim of the analysis of loss of methylation was to find the optimal drug
dose treatment strategy for Hs-27 cells. In general, a well-defined treatment strategy
for DAC is not available. However, literature search revealed that the main dose
schedule of DAC lies in the micro-molar range (Yoo and Jones 2006). To determine
the optimal dose in Hs-27 cells I conducted experiments with a previous published
dose range from 0-20µM (Juttermann, Li et al. 1994). Firstly, I needed to determine a
dose range in which the cells still divide, since DAC is S-phase dependent. Sec-
ondly, published studies suggested I need more than two rounds of replication to see
an effect of loss of DNA methylation. Therefore, the detection of loss of DNA methy-
lation is dependent on the rounds of replication a cell undergoes. After one round of
replication the DNA is hemimethylated, while in the second round of replication two
demethylated strands and 2 hemimethylated strands are the result (Jones, Taylor et
al. 1982). The duration of the treatment depends therefore on the doubling time of
the cells which in the case of Hs-27 cells, is every 21 hours.
Figure 25: S-phase dependent mechanism of DAC (Jones, Taylor et al. 1982); Me=5-Methylcytosine,
D= Decitabine. DAC gets incorporated during S-phase in the newly synthesized strand, which leads
subsequently to the trapping of the DNMT1. After the 1st round of replication two hemimethylated DNA
strands are the result. If DAC still present, after the 2nd division 50% hemimethylation and 50% de-
methylation is the result.
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However, doubling time may also be affected by the drug. Moreover, the best dose
for achieving a demethylation effect varies between the cell lines as published previ-
ously in case of cancer cell lines (Stresemann, Brueckner et al. 2006). Further, the
main focus of previous literature was on DAC induced expression level in cancer
cells (Herman, Latif et al. 1994; Herman, Jen et al. 1996; Salem, Markl et al. 2000;
Lynch, Tycko et al. 2002) and only one paper I found analyzed DAC induced expres-
sion in comparison between normal cells and cancer cells (Liang, Gonzales et al.
2002). Therefore the knowledge on how normal cells respond to the effect of DAC
treatment is poorly understood.
Accordingly, I tried two different strategies, continuous and non-continuous
treatment, to achieve a possible loss of DNA methylation induced by DAC. In the
case of the continuous treatment I treated the cells every day with the concentration
range from 0-20µM. In the experiments (Figure 14, Figure 16) I conducted this ap-
proach over the duration of 5 days. To assess any of a possible loss of DNA methy-
lation I looked first on a repetitive element, the L1P3 (Figure 14). This was due to the
fact that this is not restricted to a single copy region so any demethylation effect
could be observed throughout the genome with respect to a L1P3 repeat. The result
revealed by this experiment was that some of the CpG sites are demethylated upon
DAC treatment (Figure 14C, D). The highest decrease of CpG methylation in this
context was achieved with a concentration of 0.05, 0.1 and 0.2µM. At 0.5µM and
0.7µM this band was still visible although to a fainter intensity. At the concentrations
1, 2, 3, 10, 20µM lower molecular bands were not visible anymore. This might be
due to a difference in the loading of the DNA (explanation follows). The same effect
was achieved upon the extension of the treatment duration over 9 days (Figure 17C,
D). The quantification showed an increase in the intensity towards 0.7µM. Therefore
the duration of the treatment showed no obvious affect on the DNA methylation
status.
Further, the single copy region H19 DMR (Figure 16) was assessed for the
the loss of methylation. In this case a clear band at 962bp was visible in the HpaII
lane from 0.05-2µM which was not present in the HpaII lane of the control. This was
an indication of a partial loss of the DNA methylation in this region. The band inten-
sity decreased at higher DAC concentrations also in this experiment. Compared to
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the L1P3 element the decrease started at 2µM. Moreover the quantification in here
has to be considered with care because to different blots exhibit different back-
grounds.
In contrast, for the non-continuous treatment cells were treated every third day
with DAC. This was conducted to decrease the DAC-induced stress to the cell. The
result of the L1P3 (Figure 18) repeat revealed a partial loss of DNA methylation. A
small molecular band appeared in the treated samples from 0.05- 3.0µM in the HpaII
lane, which was very faint present in the control and in the samples with concentra-
tions 10, 20 and 50µM. (Figure 26). Moreover, also the HERV element (Figure 20)
revealed a partial decrease up to 3µM as examined upon quantification of the HpaII/
MspI bands. A common strategy in chemotherapy is that the optimal dose is deter-
mined by the fact that the maximal tolerated dose (Oki, Aoki et al. 2007).
Figure 26: non-continuous treatment of Hs-27 cells of the experiment under Fig. 13 in the result sec-
tion. A Gain of a band in the HpaII lane is visible onwards up to 3.0µM but disappeared at higher con-
centrations.
Previous studies have pointed out that Decitabine causes at high doses a cy-
totoxic effect, whereas at lower doses demethylation of the genomic sequence is the
main effect (Jones and Taylor 1980; Creusot, Acs et al. 1982; Jones, Taylor et al.
1982; Oki, Aoki et al. 2007).  Therefore, to try and induce demethylation I conducted
the non-continuous treatment with 1, 2 and 3µM in respect to single copy regions.
The H19 DMR and the AIRN DMR show cautiously explained a partial loss of DNA
methylation (Figure 21, Figure 22). This data has to be interpreted with care due to
unequal DNA loading. It should be noted that in all experiments which were con-
ducted, measuring accurate DNA concentration seemed to be difficult. Although the
ethidium bromide fluorescence often indicated similar loading of the DNA, the DNA
blot indicated a decrease in the signal intensity with higher concentrations of DAC.
For all experiments the Nanodrop OD240nm measurement was taken accurately
measure DNA concentrations for the digestions. Nanodrop measured DNA concen-
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tration may have been inaccurate because DAC induces a stress response upon
which the RNA level increases, perhaps interfering with measurement of DAC con-
centrations. A solution of this problem would be to treat DAC treated DNA with
RNaseI before measuring the concentration of DNA. Another issue that may have
altered the treated samples compared to the control sample is that DAC might have
a different UV-vis absorption that may have affected the accuracy of DNA concen-
tration measurements. To examine this I measured the absorption of 1mM CTP and
1mM DAC as well as 1mMCTP/DAC. The result was that 1mM CTP had an absorp-
tion at 273nm, 1mM DAC had the absorption at 243nm and both together at 243nm.
This leads to the conclusion that there is a slight difference in the absorption be-
tween the control (273nm) and the DAC treated samples (243nm). Whether this was
responsible for the inaccuracy of measuring DAC treated DNA concentrations re-
mains still unclear.
3.3 Cytotoxicity
Another feature throughout the experiments was that the higher the concen-
tration of DAC the slower the cells divide and more cells died by apoptosis. This is
primarily mediated by the cytotoxic effect of DAC. The cytotoxic effect is the result of
the trapping of the Dnmt1 (Juttermann, Li et al. 1994). However, the downstream
effects of this trapping are not really clear. When the cell gets the signal to divide the
cell enters the cell cycle. During this time a cell has to pass a number of checkpoints
that measure if the cell is in a healthy state e.g. during G2/M checkpoint a cell gets
examined if the replication occurred correctly during S-phase. If DNA damage had
occurred the cell may cell may go into apoptosis, if the mistakes were not repaired.
The most important molecule that pushes the cell in cell cycle arrest is the trans-
ducer p53. It was previously shown that DAC is able to induce p53 (Karpf, Moore et
al. 2001). In another study by Karpf et al. they showed that the bulky DNMT1-DAC
adducts can induce the expression of p21 through activation of p53. In this study
they used human lung cancer cell lines H549 (WT p53) and H1299 (p53- null) cells.
p21 is a downstream target of p53 and upon DAC treatment p21 was only activated
in H549 cells and not in H1299 cells. In these cell lines the promotor of p21 was un-
methylated and therefore this study shows that the primary signal that leads to the
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activation of p21 is DNA damage independent of demethylation (Zhu, Hileman et al.
2004). Through the activation of p21 the cell enters G1 arrest. This study also indi-
cated that Decitabine might have other effects than demethylation. Palii et al demon-
strated that DAC induces double strand breaks and this activated the main sensors
ATM and ATR (Palii, Van Emburgh et al. 2008). In addition, Wang et al have shown
that the activation of p21 is dependent on the activation of ATM and ATR which me-
diate certain posttranslational modifications (Ser15-phosphorylation and Lys320-
acetylation) of p53, which only then is able to activate p21 (Wang, Zhao et al. 2008).
On the contrary another study has shown that DAC is able to induce p21 independ-
ently of p53 (Nieto, Samper et al. 2004). The tumor suppressors p53 and p21 can be
induced by treatment independent of its demethylation capacity. As mentioned
above DAC has besides its demethylation capacity also the ability to induce cytotox-
icity. It was previously published that the demethylation effect is primarily mediated
at low concentrations whereas the cytotoxicity effect is initiated at higher concentra-
tions (Jones and Taylor 1980; Creusot, Acs et al. 1982; Jones, Taylor et al. 1982).
However, it was published that also lower doses can mediate a cytotoxic effect, al-
beit to a lower degree (Zhu et al 2004). Therefore to achieve a possible demethyla-
tion effect it should be more efficient to work with lower doses. This in turn means
that high doses of DAC will lead to an extensive trapping of the DNMT1 and there-
fore to an extensive damage potential, which in fact the cell cannot deal with. At
lower concentrations the cell is able to cope with the DNA damage and exits the cell
cycle arrest and enters the cell cycle again. Finally, this decrease in proliferation was
also visible by eye. In Figure 20 the control sample was MOCK treated with PBS and
they grew to over 90% confluency. In comparison the treated samples with 1-3µM
DAC showed a clear decrease in density that can be explained by the induction of
cell cycle arrest in G1 or G2 or apoptosis.
In summary for my experiments and published data it appears that non-
continuous DAC treatment at lower doses (~1µM) is the best approach to maximize
the DNA demethylation effect because cytotoxicity should be kept at a minimal level
so that the cells are still able to proliferate and replicate which is necessary to
achieve DNA demethylation and also obtain enough DNA for Southern blotting.
69
3.4 DAC and the induction of gene expression
In addition examining the effect of DAC treatment on DNA methylation, I
checked also the expression levels of two candidate genes the H19 ncRNA and
MAGE-A1. From the tiling array data as well as from the control of my qPCR assay
(SYBR green and TaqMan) I knew that the H19 ncRNA was not expressed in Hs-27
cells. Nevertheless, upon DAC treatment I induced its expression. The MAGE-A1
gene was previously published not as being expressed in normal somatic cells, but
expressed in certain tumors and its transcriptional repression is associated with DNA
methylation (De Smet, Lurquin et al. 1999). Also this gene was induced upon DAC
treatment (Figure 23).  It should be mentioned that up to now no tissue specific gene
was found that is directly regulated by DNA methylation. Therefore, if I assume that
DAC has only the ability to demethylate the DNA, I would expect for the H19 ncRNA
a 2 fold induction, which was clearly not the case. The induction I observed was 10-
100 fold. This is an argument that DAC has also secondary effects besides its de-
methylation capacity. One possibility would be that DAC induces repair pathways
that might be responsible that the unmethylated maternal allele is affected by in-
creasing the expression of ncRNA H19, whereas the expression of H19 from the
methylated allele is hindered. This might be an explanation that the results showed
in Figure 23 (A, C) do not reveal a 2 fold induction. Moreover, the transcriptional start
site of MAGE-A1 is not associated with a CpG island, but is CpG rich and due to the
limited area that I examined upon Southern blotting most HpaII sites were unmethy-
lated, although upon DAC treatment MAGE-A1 was induced. This is another indica-
tion that DAC might have secondary effects beside DNA demethylation. Interestingly,
a recent study showed that Decitabine induce the expression of 81 out of 22.000
genes. Half of the induced genes had CpG islands and from 5 randomly chosen
genes only one was associated with CpG methylation but the expression of all was
induced upon DAC treatment (Schmelz, Wagner et al. 2005).
All of this data shows that a complete DNA demethylation effect upon DAC
treatment failed to be observed. On the other hand this data shows that DAC is able
to induce the expression of 2 genes which are associated with DNA methylation
MAGE-A1 published as being associated with DNA methylation, but in Hs-27 cells
the area I look at lacks DNA methylation. To elucidate the methylation state of
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MAGE-A1 more clearly other restriction sites should be considered) as well as that
secondary effects were involved in the induction of gene expression upon DAC
treatment.
3.5 Future directions
The Myelodysplastic Syndrom (MDS) is a clonal-stem cell disorder in the bone
marrow and manifests primarily in elderly patients, on average 70 years old who
have a 2-40% risk to suffer from acute myeloid leukaemia (AML). Genetic mistakes
in a hematopoetic stem cell, causing ineffective hematopoesis, provide the founda-
tion of the disease. The patients display several symptoms like anaemia (low blood
cell count), neutrocytopenia (low white cells, neutrophils) thrombocytopenia (low
platelet count, thrombocytes). In general, AML and MDS display a reduction of nor-
mal cells, but whereas in AML cells of all blood-linages are underrepresented (red
blood cells, granulocytes and platelets) in MDS often only one of the three linages
displayed a reduction. This reduction is due to the hypercellular bone marrow with
effective apoptosis events. This is another point which sets MDS apart from AML
because in AML the increased apoptosis events are not present anymore. However,
net result is cytopenia like neutrorocytopenia and thrombocytopenia. The first results
in a high infectious risk for these individuals and the latter is the cause of bleeding.
MDS differs from AML also in genetic and chromosomal aberrations like: inversion,
deletion, translocation, monosomie and trisomie of which the most common one that
is associated with MDS is the deletion or complete loss of chromosome 5 and/or 7.
(Corey, Minden et al. 2007)
The average elderly age of affected individuals prevents an effective treat-
ment strategy. Only a small number of patients, with progessed MDS can be medi-
cated intensively with chemotherapeutic agents or make use of bone marrow trans-
plantation, the latter provides, up to now the only cure. Whereas, the overall health of
the majority of patients make such treatment approaches impossible. Due to the fact,
that epigenetic aberrations like DNA-methylation associated gene silencing (e.g.
p15INK4B(Uchida, Kinoshita et al. 1997), CALCA, CDH1 (Vidal, Paixao et al. 2007))
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also play a role in the development of the disease, provides an innovative treatment
starting point for epigenetic agents, like Decitabine.
Decitabine is FDA (Food and Drug Administration) approved and is used in
the treatment of MDS. So far it is known that Decitabine at a low dose is able to re-
verse DNA methylation pattern and contributes to cell differentiation and prolifera-
tion, via the activation of before DNA methylation associated silenced genes. How-
ever, the downstream effects of Decitabine after DNA demethylation are still un-
known. We would like to know how Decitabine exerts its function(s) in MDS patients
and investigate the possibility of the involvement of macro non-coding RNAs.
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4. Materials and Methods
4.1 Bioinformatics
Table 1 indicates the name of the analyzed region and their respective se-
quence coordinates that were retrieved from the UCSC genome browser
(http://genome.ucsc.edu/ March 2006 hg18). Interspersed elements were identified
with the Repeat Masker software (http://www.repeatmasker.org/), using standard
parameters. Moreover, the repeat masked sequences were used for creating gene
maps with Gene Construction KitTm v 2.5 (Textco, Inc.), and according to these maps
DNA blot probes were designed.  The following Accession numbers were used to
obtain the sequences of the indicated elements: satellite2: X72623 ((Weisenberger,
Campan et al. 2005)); HERV: M10976 (Repaske, Steele et al. 1985); LINE M13002
(Bourc'his and Bestor 2004). These sequences were blasted with the option BLAT
on UCSC browser (hg18).
Analyzed element Chromosom:position Reference
H19 DMR chr11: 1972987-1975651 (Jinno, Sengoku et al. 1996)
AIR DMR chr6: 160346236-160347473 (Smrzka, Fae et al. 1995)
KCNQ1OT1DMR chr11: 2676987-2678663 (Beatty, Weksberg et al. 2006)
DLK1 DMR chr14: 100333007-100341006 (Geuns, De Temmerman et al.2007)
PWS DMR chr15: 22751129-22751302 (Zeschnigk, Schmitz et al. 1997)
OCT4 chr6: 31240093-31246430 (Freberg, Dahl et al. 2007)
MAGE-A1 chrX: 152134716-152139310 (De Smet, Lurquin et al. 1999)
SINE(AluJb) chr6: 160311821-160312130 -
LINE(L1P3) chr9: 23095114-23101238 (Bourc'his and Bestor 2004)
HERV (LTR) chr19: 20721466-20730278 (Repaske, Steele et al. 1985)
Satellite2 chr10: 41799625-41800157 (Weisenberger, Campan et al.2005)
mt chrM: 6,119-6,662 -
Table 2:  Chromosomal location of the investigated regions (USCS genome browser hg18).
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4.2 PCR reaction
Primers for the PCR reaction were designed with the Primer3 programme
(http://fokker.wi.mit.edu/primer3/input.htm), using standard parameters and were
synthesized by VBC-BIOTECH (Vienna) with standard HPLC purification. The prim-
ers were ordered in a lyophilized form and were then dissolved with TE buffer to a
final concentration of 100pmol/µl (stock). The PCR reaction was conducted with a
1:10 dilution of the primer stock. Table 2 shows all used primer pairs. The PCR pro-
gram was as followed: 1. 95°C- 3min, 2. 95°C- 30 sec, 3. 59°C- 30sec, 4. 72°C-
45sec, 5. 72°C-7min (step 2-4: 34 cycles). The PCR reaction was conducted in a
25µl volume using the following ingredients: 5µl of 5xGoTaq Flexi Buffer (Promega),
0.5µl of dNTPs (10mM), 4µl of Betaine (5M), 0.125µl of GoTaq (5U/µl) Polymerase,
1µl of each primer, 1µl of MgCl2 (0.4/0.48/0.60/0.70/0.80/1.0/1.2/1.6 mM for optimi-
zation) and 10.875µl of H2O.
Probe name Forward primer Reverse primer Length
hH19mp GATATGGCCCGATACGAAGA AGTTGTGGAATCGGAAGTGG 592bp
hDLK1mp GTCACCCTAAGGCTGCTGAG TGAGACAGCAGGAGAGCAGA 582bp
hPWS mp GTGGAAGGTGCACAAGGAAT TTCCTAGCCTGCTTTTTGGA 616bp
hAluJbmp AAACGAGGTCAGGCTGAGAA AGGCCAGCTGGGTTAATTTC 411bp
hHERV(gag)mp CCTTCTGGGCTCTCCTCTT TTTGAGTCCACAGTGCTTGC 574bp
hL1P3mp AACTTCCAGAGGAGCGATCA AGTACGCCGTGGTTTTCCAG 606bp
hOCT4mp CTGGCACTCTCTCAGGCTCT TTCAGCAAAGGTTGGGAAAC 532bp
hMAGE-A1mp ACACTTTTCGTATCTTCCAAGG TGCCAACGTGACAATCAAAT 607bp
hSat2mp CCATAGGCCACATTGCACTT TCAGTGAGGCCAAGTTTGAA 533bp
hMTmp CCATCATAATCGGAGGCTTT ATTCCGAAGCCTGGTAGGAT 600bp
Table 3: PCR primers in 5’ to 3’ direction and the length of the PCR products are indicated.
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4.3 Gel Elution of PCR fragments
The PCR reactions were loaded on a 0.8-2% agarose gel, run in 1xTAE buffer
and stained for 1hr in ethidium bromide (see point 16. chemicals/solutions). The
bands of interest were cut out and purified using the Wizard SV Gel and PCR Clean-
Up System (Promega), according to manufacturer’s protocol.
4.4 Cloning into pGEM -T-Easy vector
The PCR fragments were cloned into the pGEM-T-Easy vector (Promega) ac-
cording to the manufacturer’s protocol. In brief, for each PCR fragment a 1:1 and 1:3
(vector : insert ratio) ligation reaction was conducted. The ingredients were mixed
according to the protocol and the whole reaction was incubated for 1 hour at room
temperature.
4.5 Transformation
Chemo-competent bacteria from the E. coli strain DH5α, stored at -80°C,
were thawn for 30 minutes on ice. The whole ligation reaction was added into the
tube and incubated on ice for additional 30 minutes. Heat shock was conducted on
42°C for 1 minute followed by 2 minutes of incubation on ice. Afterwards, 250µl of LB
media were added. The bacteria were placed on 37°C for 1 hour shaking at 300rpm
in the thermo mixer. The whole transformation was plated out on LB/ amp /X-gal/
IPTG (see point 16. chemicals/solutions) plates and left over night on 37°C.
4.6 Mini Prep
White colonies were picked and inoculated in 3ml LB/amp (see point 16.
chemicals/solutions) media for the mini prep and incubated on 37°C over night. On
the next day, 1.5ml of these cultures were centrifuged (Eppendorf centrifuge 5417C)
at 14000rpm for 1min, the supernatant was discarded and the pellet was
resuspended in 100µl of P1 solution (resuspension buffer). 200µl of P2 (lysis buffer)
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were applied and the tubes were incubated for 5min at RT. 200µl of P3 (neutraliza-
tion buffer) were added, mixed and 400µl of Chloroform were applied, vortexed and
incubated for 15 minutes on ice. The samples were centrifuged for 10 minutes at
14000rpm and the supernatants (~400µl) were transferred into new tubes, containing
1ml of 96% of ethanol (EtOH). Tubes were centrifuged at 13500rpm for 20 minutes
at 4°C and the supernatant were discarded. To each pellet 500µl of 70% EtOH were
added, incubated for 5 minutes and centrifuged for 5 minutes at 13500rpm at 4°C.
This washing step was done two times.  After the pellet had been air-dried it was
dissolved in 60µl TE buffer, vortexed and placed for over night on 55°C. For confir-
mation of the right fragment in the vector ~10µg of DNA was digested with an appro-
priate enzyme, incubated over night on working temperature and loaded on a 0.8%
or 2% agarose gel. After 1 hour of staining in ethidium bromide a picture was taken
and the digestion pattern was confirmed with the “in silico” predicted one that was
created with Gene Construction KitTm v. 2.5 (Textco, Inc.).
4.7 Amplification (Maxi Prep) and DNA preparation
The amplification of the constructs was conducted in a 2-step-culture proce-
dure. Tubes were prepared with each 3ml LB/amp media. To each tube, 20µl of the
miniprep culture were added and placed for 8 hr on 37°C shaking. The 3ml culture
was inoculated in 250ml LB/amp media and incubated over night on 37°C.
Plasmid isolation was conducted according to the manufacturer’s protocol (Promega
PureYieldTM Plasmid Midiprep System) either by purification by centrifugation or pu-
rification by vacuum. The DNA was eluted from the column with 800µl of TE buffer
and was precipitated by standard procedures (Sambrook, Fritsch et al. 1989). 10µg
of each construct were sent for sequencing to VBC-BIOTECH (Vienna), using stan-
dard primers from T7 promotor.
4.8 Cell culture and DAC treatment
Human-foreskin-fibroblasts (Hs-27 HFF, a primary human differentiated cell
line) were quickly thawn up at 37°C. The vial content was transferred to a tube con-
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taining 10ml of DMEM media (see point 16. chemicals/solutions/kits). The tube was
centrifuged at 1050rpm for 5 minutes, the supernatant was removed and the cells
were resuspended in 5ml of DMEM media (see point 16. chemicals/solutions/kits).
The cell suspension was transferred to a T80 flask, containing 13ml of DMEM media
and cells were grown until they were confluent. For 5-aza-2’deoxycytidine (DAC,
Sigma) treatment cells at passage 9, 10, 11, 16 were used. The cell-seeding number
in all experiments was 3*105 cells per 10 or 15 cm dishes. DAC (Sigma) treatment
started post 24 hours of seeding. The media-change and drug supply was repeated
every third, (non-continuous treatment) or every day, (continuous treatment). Con-
centration range is listed in table 3. Cells were split according to necessity and con-
fluence using Trypsin. DNA and/or RNA was isolated after either 5 or 9 days of drug-
treatment.
Con. (µM) 0.05 0.1 0.2 0.5 0.7 1 2 3 10 20
stock 0.1mM 0.1mM 0.1mM 0.1mM 0.1mM 0.1mM 0.1mM 0.1mM 1mM 1mM
Table 4: The concentration (con. µM) range for the treatment of Hs-27 cells is given in the upper
panel and the stock either 0.1mM or 1mM is given in the lower panel. The concentration range ac-
cords to a final volume of 20ml DMEM media (see point 16. chemicals/solutions/kits).
As DAC is a toxic compound all steps were performed under the cell culture
hood and gloves are used all the time. Everything that came into contact with DAC
was disposed into the toxic waste.
4.9 DNA isolation
The media containing DAC was taken off and transferred into a bottle and
trashed into toxic waste. 2.6ml of lysis buffer (see point 16. chemicals/solutions/kits)
were applied and cells were scraped down using a cell scraper. The cells were
transferred into a 15ml Falcon tube and incubated on 55°C overnight.  On the next
day, 300µl of saturated NaCl were applied to each tube and mixed for 1 minute. The
suspension was centrifuged at 14.000rpm for 10 minutes. 800µl of supernatant were
transferred into a fresh tube. 500µl of isopropanol were added, mixed for 1 minute
and centrifuged again for 10 minutes at room temperature. The supernatant was re-
moved and the pellet was washed two times with 70 % EtOH. The pellet was dis-
solved in 50-70µl of TE buffer, 55°C over night.
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4.10 DNA blotting
10-15µg of DAC (Sigma) treated Hs-27 DNA was digested with a suitable en-
zyme (Fermentas/ Roche) and incubated overnight according to their working tem-
perature. For analyzing the loss of methylation (LOM), methylation sensitive restric-
tion digests were preformed using HpaII (Fermentas) as a methylation sensitive en-
zyme, which recognizes a CCGG motif and cuts exclusively when the CG is unmeth-
ylated. In addition, the methylation insensitive isoschizomere MspI (Fermentas), that
recognizes CCGG, but cuts either if CG is methylated or unmethylated, was used.
The digestion reactions were mixed with an appropriate amount of loading buffer,
loaded on a 0.8% TBE gel together with a 1kb DNA ladder (Fermentas) and run at
5V/cm or 6V/cm. The gels were stained in ethidium bromide (see point 16. chemi-
cals/solutions/kits) and a picture was taken. The gels were denatured in denaturing
solution (see point 16. chemicals/solutions/kits). For DNA blotting, a tray with dena-
turing solution covered by a glass plate was prepared. Before the 3MM Whatman
papers (VWR International Gmbh) were placed on the glass plate, they were prewet
in denaturing solution. The ends overlapped the bottom and top of the glass plate
and reached into the denaturing buffer. A pipette was used for removing residing air
bubbles between the papers and glass plate. The gel was then placed upside down
on the 3MM Whatman papers and air bubbles were rolled out with a pipette. The gel
was then covered with a Hybond-Nylon membrane (HybondTM-XL blotting membrane
(Amersham, GE Healthcare), which was prewet for 1 minute in MQ water and addi-
tional 5 minutes in denaturing solution. On top of the membrane three additional
3MM Whatman papers were placed. Paper towel stack was put on the top, covered
with a glass plate and weight. DNA transfere was preformed for at least 18 hours.
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4.11 DNA Blot re-hybridization (“stripping”)
Hybond-Nylon membranes were washed two times for 30 minutes in 40mM
NaOH, were washed three times with H2O and neutralised in 20mM Na2HPO4.
Thereafter the membranes were pre- hybridized in Church buffer.
4.12 Probe labelling and cleaning
On the same day as the blotting procedure was preformed, probes were
radioactively labelled. 20-30ng of the in 14µl of H2O denatured at 99°C for 5 minutes
cooled for 2 minutes on ice. The Cold Mix, containing for 1 approach 6µl CTG/ 20µl
LS buffer and 1µl of the Klenow fragment (2U/Fermentas). During the time the probe
denatured on ice, 2 µl of 32α-P-ATP were added to the Cold Mix and to each probe
sample 29µl of the radioactive Cold Mix was added. The samples were labelled over
night.
On the next day, the probe was cleaned using Sephadex G50 columns. A 1ml
plastic syringe was used as a column, the barrel was removed and aquarium wool
was placed at the bottom. The column was placed into a 15ml tube. The whole sy-
ringe was filled up with Sephadex solution by using a Pasteuris pipette and centri-
fuged at 3000rpm for 3 minutes at RT (HERAEUS, MEGAFUGE 1.OR). The column
was transferred into a new 15ml tube that contained a screw cap tube at the bottom.
To the probe 60µl of TE buffer were applied and the whole content of the vial was
transferred onto the column and centrifuged at 3000rpm for 3min (HERAEUS, Bio-
fuge primo). A 1:100 dilution of the labelled probe in TE buffer was used to assess
the counts per minute with the Scintillation counter (liquid Scintillation Analyzer
1600TR).
After the blot was disassembled and the membrane pre-hybridized for 30
minutes in Church buffer (see point 16. chemicals/solutions/kits), the probe was
mixed with ~30ml of Church buffer and applied to the hybridization bottle. Hybridisa-
tion was carried out at 65°C for at least 18 hours. The membrane was washed two
times with pre-warmed (65°C) Wash Buffer (see point 16. chemicals/solutions/kits).
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The membrane was wrapped into plastic foil, and placed into a film cassette and ex-
posed to a PhosphoImager plate (Fuji). After the exposure the plate was scanned on
Typhoon 8600 Variable Mode Image scanner. The picture was analyzed with Adobe
Photoshop 7.0 and bands were quantified with ImageJ.
4.13 RNA isolation
DAC treated Hs-27 cells were trypsinized and the cell pellet was resuspended
in 2ml of TRI reagent (Sigma), incubated for 5 minutes at room temperature and
stored at –20°C. The samples were transferred to 1.5ml tubes. 100µl of BCP were
added per ml, mixed, incubated for 10 minutes at room temperature and subse-
quently centrifuged at 13000rpm for 15 minutes. The upper phase was transferred
into a fresh tube containing 500µl of isopropanol, mixed, incubated for 10 minutes at
room temperature and centrifuged at 13000rpm for 15 minutes. The pellet was
washed with 1ml of 70% EtOH (diluted with DPEC treated, autoclaved H2O), mixed
and centrifuged for 10min at 13000rpm. Each pellet was dissolved in 100µl RNA
storage solution (Ambion). According to the concentration an appropriate amount of
RNA was used for cDNA preparation (see below). The rest of the RNA was stored at
–20°C as precipitate, with 2.5 volume of EtOH + 10% 5M NaAc.
4.14 cDNA preparation
cDNA preparation was performed using the DNA-free Kit (Ambion) and the
Revert Aid Kit (Fermentas). 4µg of RNA were used for cDNA preparation. DNase
digest was carried out by adding 1µl of DNase (supplied with the Ambion kit), 3.3µl
of 10x DNA-free buffer in a final volume of 33µl. The reaction was incubated 30 min-
utes in the thermo mixer at 37°C. 5µl of inactivation solution were added, incubated
for 2 minutes at room temperature and centrifuged for 90 seconds at 13000rpm on
4°C. After this step, 33µl of the supernatant were transferred into a PCR tube and
3µl of random hexamer primers (supplied with Fermentas kit) were added to each
sample. The samples were denatured in the PCR machine at 70°C for 5 minutes and
then cooled down for 4°C, and placed on ice. A pre-mix was prepared containing
12µl of 10xbuffer, 6µl of dNTPs (supplied with Fermentas kit) and 3µl of RNase in-
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hibitor (supplied with Fermentas kit). Into each PCR tube 21µl of pre-mix were
added, which in turn was divided into one tube containing 38µl as total volume (+RT)
and one tube containing 19µl in total (-RT). All tubes were then incubated for 5 min-
utes at 25°C in the PCR machine and thereafter 2µl of Reverse transcriptase (sup-
plied with Fermentas kit) were added to the +RT approach. At last the full RT pro-
gram was performed including the following steps: 25°C for 10 minutes, 42°C for 60
minutes, 70°C for 10 minutes and 4°C.
4.15 qPCR
Primers and the probe (Table 4) were designed using PrimerExpress® Soft-
ware v2.0 (Applied Biosystems) and qPCR was conducted using the ABI Prism 7000
Sequence Detection System. Primers were ordered at VBC-BIOTECH (Vienna) with
standard HPLC purification, and were obtained in a lyophilized form. Primers were
diluted with embryo water to 100pmol/l. The working concentration of the primers
was 10µM (dissolved in embryo water). For quantification purpose standard curves
were generated using 1:1, 1:4, 1:16 and 1:64 dilutions of the cDNA of Hs-27 cells.
The qPCR was normalized to RPLPO (ribosomal protein, large, PO) as well as
GAPDH. The qPCR assay for H19, MAGE-A1 and RPLPO was a SYBR green assay
and for normalization to GAPDH, a TaqMan Assay was used. In case of the SYBR-
assay a master mix was prepared with 2xuMM buffer, forward primer (10µM), re-
verse primer (10µM) and embryo H2O. In terms of the TaqMan assay a master mix
was prepared with 2xuMM buffer, forward primer (10µM), reverse primer (10µM),
embryo H2O and 50µM GAPDH Taqman probe. In each well of the 96-well plate,
which will be used, firstly 20µl of Master mix were applied and then 5µl of template
was added. The template for this purpose was the cDNA prepared under the point
cDNA preparation. One qPCR approach was conducted using the +RT sample and
one approach was conducted using the –RT approach, as a control. In addition three
wells were carried out with embryo water as the template serving as a second con-
trol. As in the case of the –RT approach also the water approach showed no specific
amplification. Conditions for the reaction in the ABI Prism 7000SDS were 5 minutes
at 95°C 40 cycles of 95°C 15 seconds and 60°C for 1 minute. qPCR data was ana-
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lysed using the manufacturer’s protocol (Applied Biosystems). All reactions were
conducted in 3 technical replicas.
RNA name forward primer reverse primer
H19 ncRNA GTGTGACGGCGAGGACAGA TCCGTGGAGGAAGTAAAGAAACA
MAGE-A1 TGAGGGACGGCGTAGAGTTC GTTGGCCTGTCCCCTGAAA
TGAAGGTCGGAGTCAACGG ACCAGAGTTAAAAGCAGCCCTGAPDH (TaqMan)
GAPDH TaqMan probe TTGGTCGTATTGGGCGCCTGGT
RPLPO CCACGCTGCTGAACATGCT TCGAACACCTGCTGGATGAC
Table 4: qPCR primers for measuring expression levels of H19 ncRNA and MAGE-A1 in DAC treated
Hs-27 cells; primers are given in 5’ to 3’ direction.
4.16 RNA-chip
The RNA expression tilling array experiment was performed by Irena Vlatkovic, a
Ph.D. student in the lab.
4.16.1 Sample preparation
6.5µg of total RNA, isolated from Hs-27 cells, was treated with DnaseI and
dissolved in 16µl DEPC ddH2O. For first-strand cDNA synthesis 16.5µl were used as
a template by using 5µg Random Hexamer primers in a total volume of 35µl accord-
ing to Superscript II Reverse Transcriptase standard protocol. Second-strand cDNA
synthesis was performed by adding 76µl nuclease-free ddH2O, 30µl 5× Second
strand buffer, 3µl 10mM dNTP, 4µl DNA Polymerase I, 1µl E. coli DNA Ligase, 1µl
RNase H, followed by 2hour at 16°C. 2µl of T4 Polymerase (5U/µl- Invitrogen) were
added and cooled for additional 10min at 16°C.  cDNA cleaning was conducted with
QIAquick PCR Purification Kit. Precipitation and incubation on -20°C overnight fol-
lowed and the cDNA was recovered by was recovered by centrifugation at
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13,200rpm for 30min at 4°C. The pellet was re-suspended in 14~18µl nuclease-free
ddH2O.
‘Input sample’ preparation was conducted by isolation of 100µg of Hs-27 ge-
nomic DNA followed by treatment with RNase A (final concentration: 25µg/ml) over-
night at 37°C. 15µl Proteinase K (10mg/µl) were added for protein digestion at 55°C
for 2~3hours. 1ml of genomic DNA, Phenol-Chloroform exacted, was sonicated 5min
on the condition of 20% power with 20s on/1min off pulse. The distribution of the
sonicated DNA was checked in 2% agarose gel. Each 10µg sonicated genomic DNA
was cleanuped with one column from QIAquick PCR Purification Kit according to the
manufacturer protocol. After ethanol precipitation, the input DNA was recovered in
certain volume of nuclease-free ddH2O.
4.16.2 Sample quantification and qualification
Concentration was measured on NanoDropND1000 spectrophotometer and ad-
justed between 300ng/µl to 500ng/µl. The minimal total amount of each sample was
4.5µg. The 260/280 absorbance ratio of DNA samples was more than 1.6. To meas-
ure the distribution of the samples Agilent 2100 Bioanalyzer with Agilent DNA 7500
kit was used according to the manufacturer protocol. The size range of DNA samples
was between 100bp to 800bp.
4.16.3 Sample hybridization
The Enriched and Input samples were sent to Imagenes (“Berlin”), hybridiza-
tion and scanning was performed by the NimbleGen service in the company. For
normal hybridization, the Enriched sample (ds-cDNA) labeled with Cy5 Dye and the
Input sample (ds-gDNA) labeled with Cy3 Dye were co-hybridized to one NimbleGen
HIRTA chip.
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4.17 Chemicals, Solutions and Kits
Chemicals/ Materials
Agarose Biozym
5-aza-2’deoxycytidine Sigma
Betaine Sigma
BCP Sigma
Chloroform Sigma
DMEM Invitrogene
dNTPs 10mM each
(dATP, dCTP, dTTP, dGTP) Fermentas
Ethanol (96%) Merck
EDTA Sigma
Ethidium bromide Fluka
Gentamycin (10mg/ml) GibcoBRL
L-Glutamine GibcoBRL
X-gal Merck
Isopropanol Merck
IPTG Merck
LB agar Roth
MgCl2 Sigma
NaCl Sigma
Natriumacetate VWR
PBS Qbiogene
RNA storage solution (RSS) Ambion
SepahdexTMG-50 Amersham
SDS Applichem
TRI reagent Sigma
Trypsin GibcoBRL
Whatman paper VWR
Enzymes
HpaII/ MspI/ EcoRI/ BglII/ BstXI/
PvuII/NcoI/RsaI/Cfr421/AluI/DraIII/SphI
Buffer: Orange, Red, Green, Tango
Fermentas
Klenow fragment Roche
ProteinaseK Qbiogene
Taq polymerase Roche
Kits
DNA- free Kit Ambion
Reverta Aid first strand cDNA Synthesis Kit Fermentas
Pure YieldTM Plasmid Wizard PCR Clean-Up
System
Promega
PureYieldTM Plasmid Midiprep System Promega
GoTag Flexi DNA polymerase Promega
QIAquick PCR purification Kit Qiagen
Agilent DNA 7500 kit Agilent
Marker
1kb DNA ladder Fermentas
32α-P-ATP New England Nuclear (Perkin Elmer)
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Solutions
(All solutions were prepared with MiliQwater)
TE-Buffer pH 8.0: 10ml 1M Tris.HCl pH 8.0 + 2ml 0.5M EDTA up to 1l with H2O
1M Tris pH 8.5 (for 100ml): 12.1g Tris with HCl to pH 8.5 up to 100ml with H2O
50x TAE buffer: 242g Tris + 57,1ml Acetic acid + 100ml 0.5 M EDTA pH 8.0 fill up to
1l with H2O.
10x TBE buffer: 108g Tris, 55g Boric Acid, 0.5M EDTA pH 8.0 up to 1l with H2O
5xTen9: 250ml Tris pH9.0 + 200ml 0.5M EDTA pH 8.0 + 40ml 5M NaCl
0.5M EDTA pH8.0: 186.1g EDTA pH to 8.0 with NaOH up to 1l with H2O, autoclave
20% SDS: 200g SDS up to 1l with H2O
P1 (resusspension buffer): 6.06g Tris base/ 3.72g Na2EDTA.2H2O add 800ml H2O
and adjust to pH 8.0 with HCl to 1l with H2O  (RNase: 100mg/l)
P2 (lysis buffer): 8.0g NaOH in 950ml H2O + 50ml 20% SDS up to 1l with H2O.
P3 (neutralization solution): 294.5g/500ml H20 KaAc, adjust to pH5.5 with acetic acid
add H2O to a final volume of 1l
ProteinaseK: 10mg/ml
Na2HPO4:  (0.5M): 89g Na2HPO42H2O/l adjust to pH 7.2 with H3PO4
Lysis buffer: (for 20ml) 4ml 5x TEN9 + 1ml 20%SDS + 1.0 ProteinaseK(10mg/ml) +
14ml H2O
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10M NaOH: 800g NaOH in 1600ml H2O, 4 hour rotating, fill up to 2l with H2O
40mM NaOH: 4ml of 10M NaOH up to 1l with H2O
CTG mix: 100µM dTTP + 100µM dCTP + 100µM dGTP + BSA 2mg/ml
LS mix: stock: 25ml 1M HEPES pH6.6 + 25ml 250mM Tris-Cl pH8 / 25mM MgCl2
6H2O/ 50mM beta-mercaptoethanol + 25ml OD U/ml hexameres
Denaturing solution: 50ml 10M NaOH, 300ml 5M NaCl/l
Church buffer: 500ml 0.5M Na2HPO4 + 350ml 20%SDS + 2ml 0.5M EDTA
Wash Buffer: 40ml 0.5 Na2HPO4.2H20 (pH7.2) + 50ml 20% SDS up to 1l with
MQH2O
DPEC-H2O: 900ml H2O + 900µl DPEC (shake for 20 seconds, 2 hours on 37°C)
DMEM media: (for 200ml): 177ml DMEM (high glucose) + 20ml FCS + 2ml L-
Glutamine (200mM) + 1ml Gentamycin (10mg/ml)
Ethidium Bromide (2mg/ml): 20mg EtBr in 10ml H2O; 500µl EtBr in 1000ml H2O
LB media: 10g LB media + 400ml of H2O
LB/amp plates: 400ml Circlegrow Agar + 400µl Ampicilin (stock: 50mg/ml in H2O:
EtOH / 50:50)
X-gal: 50mg X-Gal in 1ml N,N- dimethylformamid
IPTG: (0.1M) 1g of IPTG dissolved in 41.7ml autoclaved, filter sterile by using a 50ml
Syringe + Syringe filter
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0.8% agarose gel: 3.2g agarose in 400ml TAE
2.0% agarose gel: 8g agarose in 400ml TAE
Loading buffer: 0.5% Xylenol orange (0.25g) + 30% Glycerol 15ml in 1x TAE up to
50ml
3M NaAc pH 5.2: 246.1g NaAc/l and adjust to pH 5.2 with acetic acid
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